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Abstract 
 
Investigating neurodegenerative diseases with small molecule modulators 
Reka Rebecca Letso 
 
Elucidation of the mechanisms underlying cell death in neurodegenerative 
diseases has proven difficult, due to the complex and interconnected architecture of the 
nervous system as well as the often pleiotropic nature of these diseases. Cell culture 
models of neurodegenerative diseases, although seldom recapitulating all aspects of the 
disease phenotype, enable investigation of specific aspects of these disease states. Small 
molecule screening in these cell culture models is a powerful method for identifying 
novel small molecule modulators of these disease phenotypes. Mechanistic studies of 
these modulators can reveal vital insights into the cellular pathways altered in these 
disease states, identifying new mechanisms leading to cellular dysfunction, as well as 
novel therapeutic targets to combat these destructive diseases. 
Small molecule modulators of protein activity have proven invaluable in the study 
of protein function and regulation. While inhibitors of protein activity are relatively 
common, small molecules that can increase protein abundance are quite rare. Small 
molecule protein upregulators with targeted activities would be of great value in the study 
of the mechanisms underlying many loss of function diseases. We developed a high-
throughput screening approach to identify small molecule upregulators of the Survival of 
Motor Neuron protein (SMN), whose decreased levels cause the neurodegenerative 
disease Spinal Muscular Atrophy (SMA). We screened 69,189 compounds for SMN 
upregulators and performed mechanistic studies on the most active compound, a 
bromobenzophenone analog designated cuspin-1. Mechanistic studies of cuspin-1 
revealed that increasing Ras signaling upregulates SMN protein abundance via translation, 
an effect which may be associated with the translational regulator mammalian target of 
rapamycin (mTOR). These findings suggest that controlled modulation of the Ras 
signaling pathway may benefit patients with SMA. 
Small molecule modulators of a disease phenotype, such as cell death, have the 
potential to reveal novel mechanisms regulating disease processes. This was exemplified 
by a screen for small molecule inhibitors of cell death caused by a pathogenic, 
misofolded mutant huntingtin protein in a cell culture model of Huntington’s Disease 
(HD). These cell death inhibitors were found to target protein disulfide isomerase (PDI), 
an oxidoreductase known to be important in endoplasmic reticulum quality control of 
protein folding. However, our studies utilizing the small molecule PDI inhibitors 
determined that the cell death observed in this system was due to a pro-apoptotic function 
of PDI involving proteins of the mitochondrial outer membrane. We have begun studies 
aimed at identifying the binding mode of these novel small molecule inhibitors of PDI, in 
efforts to develop more potent and efficacious analogs for testing in animal models of HD. 
These studies have helped defined a novel mechanism linking protein misfolding to cell 
death, and may prove to be relevant to a broader range of protein misfolding diseases. 
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Chapter 1. Spinal Muscular Atrophy 
 
Treating inherited neurodegenerative diseases  
 
The development of pharmacological therapeutics for neurodegenerative diseases 
has been impeded by their complex etiology and the intricately entwined nature of the 
cells of the central nervous system 1. However, understanding the genetic alterations 
resulting in inherited neurodegenerative diseases, as well as the cellular pathways 
affected, may define new avenues for treatment. Monogenic diseases are particularly 
valuable as research tools, as animal models of monogenic diseases are generally 
straightforward to produce. These animal models can provide a wealth of information 
concerning the pathology of disease, as well as the underlying biochemical alterations 
resulting in cellular dysfunction.  
Monogenic inherited neurodegenerative disorders can be further classified into 
two groups based on their proposed mechanisms of action: neomorphic and hypomorphic 
disorders.  Neomorphic mutations are generally dominant, as they result from an 
“activated” mutant form of the defective protein. Hypomorphic mutations tend to be 
recessive, as they are normally caused by a severe decrease or loss of protein activity. 
Therapeutic strategies for these two types of diseases generally differ greatly, as one is 
aimed at inhibiting an active aberrant process, while the other requires substitution for the 
protein activity which is lacking. Approaches for inhibiting active processes are generally 
more straightforward than searching for methods to replace a lost function, and this is 




examples of both types of inherited neurodegenerative diseases and discusses the 
therapeutic strategies employed for each. 
 
Neomorphic neurodegenerative diseases 
 
Neomorphic diseases are characterized by excessive or ectopic activity of a 
mutated protein, resulting in cellular dysfunction and disease. Classical examples of 
neomorphic neurodegenerative diseases are those caused by expanded tri-nucleotide 
repeats. A common tri-nucleotide repeat expansion is that of the codon CAG, which 
codes for glutamine, resulting in proteins with expanded polyglutamine regions. Both 
Huntington’s disease and Spinal Bulbar Muscular Atrophy (SBMA) result from expanded 
polyglutamine stretches in a single gene.  
The genetic cause of Huntington’s disease is an expansion in the CAG triplet 
repeat in the huntingtin (htt) gene, which results in a mutant Htt protein with an expanded 
polyglutamine stretch. Wild-type Htt contains between 6 and 35 glutamines in this region, 
however expansion greater than 36 repeats has been associated with development of 
Huntington’s symptoms 2. Age of onset and severity of symptoms have been shown to be 
inversely correlated with the length of the polyglutamine stretch. ‘Genetic anticipation’ 
has been observed caused by further expansion of the polyglutamine stretch with 
successive generations, with a corresponding increase in severity and decrease in age of 
onset 3. The pathogenic effect of mutant Htt is correlated with its degree of aggregation 




aggregation 4 or enhancing clearance of the aggregated protein by stimulation of 
autophagy . 5,6
Spinal Bulbar Muscular Atrophy (SBMA) results from an expanded glutamine 
repeat in the first exon of the androgen receptor 7. The mutant androgen receptor (mAR) 
accumulates in the nucleus in a testosterone-dependent manner, potentially explaining 
why only males show the degenerative phenotype. mAR causes adult-onset, progressive 
degeneration of the lower motor neurons, though other tissues have also shown to be 
affected. Loss of neuronal input from the lower motor neurons results in atrophy of the 
innervated muscles, leading to the phenotype of weakness and eventual paralysis. The 
testosterone-lowering hormone agonist leuprorelin has been studied for its ability to 
reduce the levels of pathogenic mAR, however the results of human trials have been 
somewhat conflicting 8,9. Additionally, the small molecule ASC-J9 has been 
demonstrated to increase the clearance of the androgen receptor 10, providing another 
compound that can prevent the accumulation of the pathogenic mAR. 
The CAG triplet is not the only codon in which expansion can result in pathogenic 
effects. Diseases involving other tri-nucleotide repeats include Fragile X Syndrome and 
Friedreich’s Ataxia. Fragile X Syndrome is caused by expansion of a CGG triplet repeat, 
coding for a polyarginine tract, in the fragile X mental retardation 1 gene (FMR1) on the 
X chromosome. Mutations in FMR1 result in cognitive impairments and increased 
likelihood of childhood seizures. FMR1 protein is highly expressed in the brain and is 
believed to play a role in cortical synapse development 11 and negative regulation of 
protein synthesis at neuronal synapses . Synaptic protein synthesis has been suggested 





and inhibition of mGluR5 has been shown to be beneficial in animal models of Fragile X 
Syndrome .  13
Friedreich’s Ataxia (FRDA) is an autosomal recessive disease characterized by 
progressive sensory loss and loss of coordinated muscle movements, known as ataxia. 
FRDA is caused by an expansion of an intronic GAA triplet repeat in the frataxin (FXN) 
gene 14. FXN is a mitochondrially-targeted protein involved in biogenesis of 
mitochondrial iron-sulfer cluster proteins, which are especially important for proper 
function of the electron transport chain 15. The mutant FXN is expressed at lower levels, 
causing accumulation of mitochondrial iron and increased susceptibility to oxidative 
stress . Therefore, the treatment strategies for FRDA have been mainly aimed at 
scavenging the reactive oxygen species produced by the mitochondrial damage . 
16
17
Amyotrophic lateral sclerosis (ALS) provides an example of a gain of function 
neurodegenerative disease not attributed to expansion of triplicate repeats. Approximately 
1% of ALS cases have a discernable mutation in the superoxide dismutase 1 (SOD1) gene 
18. Mutations in SOD1 result in degeneration of the upper and lower motor neurons, 
though the sensory neurons and cognitive functions are generally unimpaired. Selective 
motor neuron death has been attributed to increased reactive oxygen species as a result of 
SOD1 mutation, and pharmacological treatments have focused on development of 
antioxidant SOD mimetics 19. 
Although differing in the exact nature of the mutation and gene affected, these 
neomorphic diseases share a common feature in that therapeutic interventions are 
generally aimed at preventing the toxic effects of the mutants, either by reducing the 




Therefore, in some ways pharmacological development is simplified, as it does not 
always require a complete understanding of the effector pathways leading to cellular 
dysfunction and disease. 
 
Hypomorphic neurodegenerative diseases 
 
Development of treatments for hypomorphic diseases are generally not quite as 
straightforward as for neomorphic diseases, as they are not caused by a pathogenic gain 
of function mutation that can be “shut down”. Countering the loss of a protein’s activity 
generally requires a thorough understanding of the underlying pathology. Metabolic 
diseases provide a good example of how understanding the biochemical pathways 
affected can lead to management of the disease state. Metabolic diseases are generally 
caused by a mutation in a single gene encoding an enzyme required for the synthesis of a 
key cellular metabolite. Disease can occur by a toxic buildup of the metabolic precursor 
or due to loss of the enzymatic product. In the case of toxic accumulation, a diet restricted 
in the precursor can resolve the condition. In Phenylketonuria (PKU) a mutation in 
phenylalanine hydroxylase prevents conversion of phenylalanine to tyrosine. Elevated 
levels of phenylalanine reduces the CNS levels of methionine and tyrosine, resulting in 
decreased levels of dopamine 20. PKU requires a strict diet low in phenylalanine in order 
to prevent the mental degeneration caused by these unbalanced metabolic processes.  
When the problem is loss of a metabolite, supplementation can markedly improve 
the course of the disease. Biotinidase deficiency, in which mutations in the biotinidase 




due to the body’s inability to properly process fats, carbohydrates and the amino acids 
leucine and isoleucine 21. Supplementation with biotin can completely prevent all 
symptoms of BTD deficiency. 
 The negative consequences of these diseases are preventable due to a thorough 
understanding of the metabolic pathways affected. However, there are many other 
diseases for which the underlying pathology is unclear, often those involving non-
enzymatic proteins. This lack of understanding often results in a lack of effective 
treatment options for these conditions. However, understanding the underlying condition 
can only get you so far. For many of these currently untreatable diseases, it is difficult to 
conceive of how one could pharmacologically remediate the absence of a protein function. 
An example of this is Duchenne muscular dystrophy (DMD), which is characterized by 
progressive degeneration of skeletal muscle, due to impairment of dystrophin. Dystrophin 
is required for proper attachment of the cytoskeleton to the basal lamina in skeletal 
muscle cells 22. In the absence of functional dystrophin, the extracellular membrane 
becomes more fragile, intracellular calcium levels increase and muscle cells undergo 
necrosis. Despite significant funding and decades of research, resulting in nearly 7,000 
articles listed in PubMed under the search “Duchenne muscular dystrophy”, the concept 
of a drug target in this disease remains untenable.  
  Another such disease is Spinal Muscular Atrophy 23, an autosomal recessive 
neuromuscular disorder that is unusual in the realm of neurodegenerative diseases, as it is 
monogenic and demonstrates simple Mendelian inheritance patterns. Approximately 98% 
of SMA cases can be identified by a deletion or inactivating mutation in the Survival of 




however, due to a gene duplication event, there exists a nearly identical copy of SMN1, 
termed SMN2. Due to a mutation in SMN2 affecting splicing, it only produces a small 
fraction of the protein produced by SMN1. This small amount of SMN rescues the 
embryonic lethality, but results in degeneration of a subset of motor neurons and 
progressive atrophy of the innervated muscles 26. Although the genetic alterations 
underlying SMA have been known since 1995 and are relatively straightforward, the 
mechanism resulting in the pathology of SMA is still unknown. The development of 
candidate therapeutics has focused on increasing the levels of SMN protein within the 
motor neuron, as without further knowledge of the underlying alterations in cellular 
pathways resulting in disease, this remains the only conceivable method of 
pharmaceutical intervention. 
 This thesis focuses on Spinal Muscular Atrophy, and the efforts made by 
ourselves and others at identifying candidate therapeutics and revealing novel molecular 
targets. 
 
Spinal Muscular Atrophy Disease 
 
Spinal Muscular Atrophy 23 is an autosomal recessive neurodegenerative disease 
characterized by progressive degeneration of lower motor neurons. SMA presents 
clinically as atrophy of the proximal muscles, while later stages of the disease often result 
in quadriplegia. SMA is the most common autosomal recessive genetic disease that is 
lethal in infancy, with an incidence rate between 1 in 6,000 and 1 in 10,000 (0.02% to 




disorders such as Duchenne Muscular Dystrophy 28. The carrier frequency has been 
estimated at 1 in 48 (approximately 2% of the population) 29. SMA is found within all 
ethnic groups. However, a study of North American populations found that the carrier 
rates varied somewhat between ethnic backgrounds. Hispanic ethnicities had the lowest 
carrier rate at 0.8%, followed by African American at 1.1%, Asian at 1.8%, Ashkenazi 
Jew at 2.2% and Caucasians carrying the highest rate at 2.7% 30. These values generally 
agree with the 2% carrier rate estimated previously, and demonstrate a relatively even 
pan-ethnic distribution. 
 
SMA disease pathogenesis 
 
In SMA, the primary step in disease progression is degeneration of the alpha 
motor neurons projecting from the anterior horn of the spinal cord 26. Alpha motor 
neurons innervate skeletal muscles and are responsible for conducting action potentials 
initiating skeletal muscle contracture. Alpha motor neurons contact their corresponding 
muscle at a region termed the neuromuscular junction (NMJ). At the NMJ, motor neurons 
provide neurotransmitters to stimulate the muscle, and also provide the muscle with 
trophic support. Loss of normal motor neuron-to-muscle communication, via physical 
damage or neurodegenerative diseases such as SMA, results in atrophy of the 
corresponding muscle 31,32.  
Therefore, although the alpha motor neurons are the tissue directly affected in 
SMA disease pathogenesis, the primary physical manifestation is muscle weakness. The 




and hips 26. Also affected are the intercostal muscles, which assist in breathing, although 
the diaphragm is generally spared. The facial muscles are unaffected, as are all sensory 
neurons, interneurons, upper motor neurons and alpha motor neurons projecting from the 
ventral horn of the spinal cord. Disease-specific targeting of sub-populations of neurons 
is not uncommon and is seen in several other neurodegenerative diseases such as 
Huntington’s disease 3. 
SMA is diagnosed first by general weakness and lack of muscle tone. In infants, it 
is often noted when the child does not reach its developmental milestones, such as being 
unable to hold up the head. Additionally, children with SMA have difficulty feeding and 
often develop a characteristic bell-shaped torso, due to the compensatory use of 
abdominal muscles for breathing as the intercostal muscles atrophy. In the clinic, 
additional tests used to confirm the diagnosis are electromyography, which records the 
electrical output capacity of a muscle group, as well as polymerase chain reaction (PCR) 
to determine whether there are mutations in the disease gene. 
 
SMA disease phenotypes 
SMA demonstrates a wide range of clinical severity, from the most severe Type 0 
to the mildest form, Type IV. SMA Type 0 demonstrates prenatal onset with a median 
neonatal survival period of 7 months 33. SMA Type I, also called Werdnig-Hoffman 
disease (OMIM 253300), is the most common form of SMA, making up approximately 
50% of SMA cases. The onset of disease is usually prior to six months of age, and these 
patients generally do not ever acquire the ability to sit or stand independently. In addition 




display tongue fasciculation (twitching of the tongue due to spontaneous contraction of 
the muscles), hyporeflexia (lack of normal reflexes), and have difficulty eating and 
breathing. Most patients develop moderate to severe respiratory problems, often requiring 
support by a breathing apparatus. These breathing difficulties often lead to recurrent 
respiratory infections, such as pneumonia, which are the most common cause of death. 
The majority of SMA Type I cases do not survive past age two, although significant 
respiratory and nutritional support can prolong life span.  
Type II patients (OMIM 253550) have an average age of onset between six 
months and two years, and also demonstrate a reduced life expectancy. They are 
normally confined to a wheelchair, as they can sit unaided but are unable to walk. These 
patients may also require respiratory support. Patients with Type III SMA, also known as 
Kugelberg-Wlander disease (OMIM 253400), usually develop symptoms after 18 months 
of age, and can often learn to walk, but often develop the need for assistance within a few 
years after onset. Type III patients can have a normal life span. The least common Type 
IV form (OMIM 271150) is termed ‘adult-onset’ as symptoms develop normally after age 
30 34. Type IV patients can usually sit and walk unaided, although they lose their ability 
for more strenuous exertion, such as continuing to participate in sports that they played 
prior to the onset of symptoms. 
 
Genetics of SMA 
 
The three common types of SMA, Types I-III, were determined to be genetically 




the chromosomal region 5q11.2-5q14 in 1990 35,36. It is of worth to note that the efforts 
aimed at identification of the gene mutated in SMA were a significant undertaking, due to 
the laborious nature of the gene mapping techniques available prior to whole genome 
sequencing. The region of interest was further refined in 1992, to the chromosomal 
region 5q13 37, and deletions within this region were noted to be a statistically significant 
occurrence in SMA patients 27. In 1995, Lefebvre, et al., identified a 500kb inverted 
duplication within the 5q13 region, which contained a duplication of a little-studied gene 
that was disrupted in a large percentage of SMA patients 24. This gene was the aptly-
named survival of motor neuron (SMN) gene.  
In the 5q13 region, there are two copies of SMN. The gene that is mutated in the 
majority of SMA cases is the telomeric gene, SMN1. The disease modifying gene is the 
centromeric copy, SMN2. The two SMN genes are nearly identical, with only eleven 
nucleotide changes, five within the coding region 24. The nucleotide alterations within the 
coding sequence are all silent 38. The promoters of the two genes share common 
regulatory elements 39,40 and the pre-mRNA sequences are 99.9% identical 41. 
Additionally, both demonstrate ubiquitous expression of mRNA and protein 24,42. 
However, Monani et al. demonstrated that the single cytosine (C) to thymine (T) 
transition at position 6 in exon 7 in the SMN2 gene resulted in alternative splicing of the 
majority of SMN2 pre-mRNA’s 41. The alternatively spliced form of SMN2 is truncated, 
missing exon 7 43. Loss of exon 7 is denoted as SMNΔ7. Although the loss of exon 7 has 
no affect on SMNΔ7 mRNA, the truncated protein translated from the mRNA, termed 
SMNΔ7, is extremely unstable and does not accumulate to a quantifiable degree in cells 




for full-length, generate the same protein produced in larger quantities by the SMN1 gene. 
However, the SMN2 gene does not produce enough full-length SMN protein to rescue 
from homozygous loss of the SMN1 gene (Figure i). 
There has been some debate over the mechanism by which the C/T transition in 
SMN2 results in skipping of exon 7. Cartegni, et al., first suggested that the nucleotide 
transition disrupted an exonic splicing enhancer (ESE) sequence required for inclusion of 
exon 7 47. This ESE motif was identified by computational analysis, which predicted 
binding by the serine/arginine-rich 48 proteins SF2/ASF, SC35, SRp40 and SRp55. SMN1 
was predicted to have a heptamer motif which was predicted to be strongly recognized by 
the splicing factor SF2/ASF. In vitro and in vivo splicing assay demonstrated that while 
the SMN1 sequence was efficiently recognized by SF2/ASF, the sequence divergence of 
SMN2 reduced its splicing efficiency greater than two-fold in these assays.  
However, it has also been argued that rather than disrupting an ESE, the C/T 
transition in the SMN2 gene created an exonic splicing suppressor (ESS) element 49. In 
this study, modulation of the levels of the SR protein SF2/ASF demonstrated only very 
mild effects on SMN2 mRNA splicing, which did not agree with the previous report 
implicating SF2/ASF as the major protein regulating exon 7 inclusion. Instead, the 
authors hypothesized that SMN2 mRNA contained an ESE, and demonstrated that this 
putative ESE is efficiently recognized by the splicing repressor protein, heterogeneous 
nuclear ribonucleoprotein A1 (hnRNP A1). Additionally, RNAi knockdown of hnRNP 
A1 as well as mutating the ESS resulted in inclusion of exon 7 in spliced SMN2 






Figure i. Low levels of SMN protein lead to SMA.  
The genomic organization of the SMN locus is depicted above. A 500kb inverted 
duplication in the SMN locus resulted in a near-exact copy of the SMN1 gene, termed the 
SMN2 gene. However, a C to T transition in exon 7 of the SMN2 gene causes the majority 
of the transcripts to be alternatively spliced to exclude exon 7. This transcript is translated 
into a mutant SMN protein lacking exon 7, termed SMN-Δ7.  SMN-Δ7 is unstable and 
quickly degraded. Therefore, the SMN2 gene produces significantly less functional SMN 
protein compared to the SMN1 gene. Upon homozygous loss of the SMN1 gene, as is 
seen in many SMA patients, the low level of full length SMN protein produced by the 
remaining SMN2 gene(s) is not sufficient to rescue motor neuron viability, resulting in 




A1 antagonized SF2/ASF binding 50, however the validity of this model is still under 
debate. 
The majority of SMA patients (over 98%) have homozygous deletions or 
mutations of the SMN1 gene 24,25. As these patients express SMN protein only from their 
SMN2 gene, this results in the patients’ cells producing a significantly decreased quantity 
of SMN protein. However, patients can have more than one copy of the SMN2 gene, due 
to the instability of the 5q13 chromosomal region. The clinical range of SMA severity 
has been strongly correlated with gene copy number 51-53. One to two copies of SMN2 
correlate with the most common form of SMA, type I, while increasing the SMN2 copy 
number to four or five correlates with the less severe Type III cases. No patients have 
been reported with homozygous loss of both the SMN1 and SMN2 genes, suggesting that 
complete loss of SMN protein is lethal during embryonic development in humans. This 
hypothesis has evidence in numerous SMN knockout animal models, which demonstrated 
that the smn null background is non-viable in organisms ranging from yeast to mice 54-57. 
SMN1 is the only gene in which mutations have been associated with SMA to date. 
However, a recent comprehensive analysis of SMA patients identified 92% of patients 
had homozygous deletions of SMN1, 3.4% had intragenic mutations, while 4.6% had no 
identifiable mutation in the SMN1 gene 58. As approximately 5% of SMA patients do not 
have an identifiable mutation of the SMN1 gene, this may indicate that mutations in yet-
unidentified genes can result in SMA. Alternatively, these cases may be misdiagnosed as 
SMA, for example resulting from an environmental toxin mimicking the symptoms of 
SMA. Toxic insults leading to or imitating neurodegenerative phenotypes have been 




been suggested in the elevated incidence of ALS observed in professional Italian soccer 
players 60.  
It is of interest to note that only Homo sapiens carry the SMN2 gene. Even species 
as genetically similar as chimpanzees lack SMN2 61, indicating that the gene duplication 
event occurred after the Homo-Pan (chimpanzee) split, which last shared a common 
ancestor circa 5-7million years ago 62. However, as the SMN2 gene is relatively evenly 
dispersed within all ethnic groups worldwide, the duplication event must have occurred 
prior to the Homo sapiens species migration from Africa, approximately 60,000 years ago 
63. The rather high carrier rate of SMA (approximately 2%) suggests that it may have 
been selected for to remain within the population, however, no evolutionary advantage 
has been identified for SMA carriers to date. One hypothesis is that it may be involved in 
viral infection, as it has been demonstrated that the SMN complex interacts functionally 
with several viruses. The Lymphotropic Herpesvirus saimiri has been shown to co-opt the 
SMN complex for assembly of their own ribonucleoproteins 64. The mouse Minute virus 
has been shown to utilize SMN for activation of viral promoters 65. Additionally, 
components of the SMN complex have been shown to be important for HIV-1 infection 66. 
Therefore, it is possible that reduction in SMN protein levels could result in increased 
resistance to viral infection or reproduction, although there is no direct evidence to 
support this hypothesis.  
 
 





In efforts to gain a better understanding of the cellular functions of SMN and the 
pathogenesis of Spinal Muscular Atrophy, animal models of SMA have been developed 
in several diverse model organisms, including Schizosaccharomyces pombe (fission 
yeast), Drosophila melanogaster (fruit fly), Danio renio (zebrafish) and Mus musculus 
(mouse). Complete loss of SMN has been demonstrated to be lethal across all species 
tested 54,57,67, highlighting the evolutionary conservation of the essential function(s) of 
SMN.  
 
SMN in Schizosaccharomyces pombe (fission yeast) 
 
The yeast protein Yab8 was identified as the yeast orthologue of human SMN in S. 
pombe 54. Other yeast species, including the laboratory workhorse S. cerevisiae, lack an 
orthologue of human SMN (hSMN). Yab8 is an essential yeast protein, and is found in the 
yeast nucleus and cytoplasm. The yeast orthologue has 24% sequence similarity to 
human SMN, with the highest similarities clustered near the N and C terminus. However, 
despite these similarities hSMN cannot rescue loss of Yab8 in yeast, indicating 
incomplete replacement of an essential function. These regions have shown to be 
important for the self-oligomerization of hSMN as well as its interaction with its binding 
proteins 68-70. The high level of conservation in these regions permits Yab8 to oligomerize 
with hSMN and bind to human Sm proteins, however Yab8 binds significantly more 
strongly with itself than with hSMN. Yab8 is found to be highly oligomerized by HPLC 
gel filtration, generally eluting in the range of 100-440kDa with no detectable monomer 




promoter also had a negative effect on yeast growth rate and colony size, indicating that 
an overabundance of Yab8 is deleterious. This effect has not been observed in mouse 
models of SMA 56, suggesting it may be a yeast-specific effect. 
Hannus, et al. also identified Yab8 as the S. pombe orthologue, and demonstrated 
that conditional knockdown of Yab8 inhibited splicing and lead to nuclear accumulation 
of polyadenylated mRNA 71. The authors additionally characterized Yip1 as the 
orthologue of human SIP1. A yeast two-hybrid screen was utilized to detect proteins 
interacting with Yab8, which identified Yip1 as a binding partner. Yip1 has 45% 
sequence similarity with the human SIP1/Gemin2, a known binding partner of SMN 72, 
and the authors suggest that Yip1 is the S. pombe orthologue of Gemin2. In vitro binding 
studies confirmed this interaction, as well as the ability of Yab8 to self-oligomerize. 
However, unlike Paushkin 54, Hannus did not observe efficient binding between the S. 
pombe Yab8 and human SMN, nor with the orthologous SIP1/Yip1, or the human Sm 
proteins, indicating the conservation of binding domains may not be as high as previously 
thought. While complete knockout of Yab8 prevented cell growth, conditional 
knockdown of Yab8 under a thiamine-repressible promoter demonstrated a severe 
splicing defect. Unspliced poly(A) mRNAs were shown to accumulate in the nucleus, 
demonstrating that Yab8 activity is required for splicing. 
 
SMN in Caenorhabditis elegans (worm) 
 
The C. elegans orthologue of SMN, CeSMN, was characterized by Miguel-Aliaga 




staining, though CeSMN is excluded from the nucleus of blastomeres during mitosis. In 
order to determine the pattern of SMN expression in the adult worms, a CeSMN-GFP 
construct was created which included 3.5kb of the region upstream of the CeSMN 
promoter. GFP expression was observed in the nucleus of hypodermal, gut, muscle and 
germ cells, which the authors claimed was unusual, as the C. elegans germline is known 
to normally silence transgene expression within the germline cells 73. Interestingly, the 
excretory cell and neurons demonstrated cytoplasmic staining, in particular in the 
neuronal processes, suggesting that CeSMN may have an important alternative function 
in these cells. RNAi knockdown of CeSMN caused late embryonic developmental arrest 
in the majority of the F1 progeny. Those progeny which continued development 
demonstrated paralysis and sterility. The most prevalent phenotype was sterility, which 
was observed even in the least affected individuals. The sterility was due to an inability 
of the germ cells to mature, due to loss of the maternally provided spliced mRNA’s 
normally packed into the maturing germ cells, indicating that knockdown of CeSMN had 
a strong negative effect on splicing in C. elegans. Overexpression of CeSMN resulted in a 
similar phenotype as knockdown, including locomotor defects and decreased number of 
progeny. This deleterious effect of overexpression has also been shown upon 
overexpression of the yeast SMN orthologue Yab8 in S. pombe 54. 
Burt and colleagues utilized a yeast two-hybrid assay to identify additional 
binding partners of CeSMN 55. This screen identified 16 putative CeSMN interacting 
proteins, many of which demonstrated similarity to proteins involved in RNA processing 
and metabolism. The interaction with RNA processing proteins suggests that many of the 




authors identified the C. elegans orthologue of human Gemin2, which they termed SMI-1, 
for SMN interacting protein-1 (40% similarity). The expression of a SMI-1-GFP 
transgene was observed throughout entire lifespan of the worm, in the gut, some nerve 
cells in the head, ventral nerve cord cell bodies and body-wall muscle cells. Knockdown 
of SMI-1 resulted in locomotor defects, paralysis and sterility in adults, and complete 
embryonic lethality, demonstrating the essential nature of this protein.  
 
SMN in Drosophila (fruit fly) 
 
 A Drosophila model of SMA was generated by creating animals with a missense 
mutation in the Drosophila SMN orthologue 74. This missense mutation (smn ) resides 
within the YG-box, a region which is important for self-oligomerization and proper 
function of human SMN protein .
73Ao
68  Homozygous mutants demonstrated lethality at late 
larval stages, rather than the early embryonic lethality seen in mammalian models , due 
to maternally-contributed smn mRNA. This mutant also displayed motor defects, 
suggesting that the Drosophila SMN orthologue was also required for neuronal health. 
The motor defects were determined to be due to dsyfunctionality of the neuromuscular 
junction (NMJ). The NMJ is made up of a motor neuron on the pre-synaptic side, which, 
upon being stimulated by an action potential, will release a neurotransmitter acetylcholine 
(ACh) in humans, glutamate in Drosophila) across the synaptic cleft. Binding of the 
neurotransmitter by the post-synaptic receptors located on the muscle cause excitatory 
postsynaptic currents (EPSCs), resulting in muscle contracture. The defects in the SMA 





(EPSCs), indicating that the signaling beginning in the pre-synaptic neuron was not being 
properly translated into contraction signaling at the post-synaptic side of the 
neuromuscular junction (NMJ). Additionally, although gross architecture of both the 
motor neuron and muscle were preserved, mild defects in synapse structure were evident, 
such as reduced clustering of the glutamate receptor. This model of SMA displayed 
significant SMA-like deterioration of motor function, which were determined to be due to 
defects at the neuromuscular junction. This defect was later shown to be rescued by 
modulation of the bone morphogenic protein (BMP) signaling pathway , suggesting a 
potential new therapeutic target, which has yet to be investigated in humans. 
48
 
SMN in Danio renio (zebrafish) 
 
 Similar axonal defects were observed in SMA model developed in zebrafish 75. 
Antisense morpholinos, which have been demonstrated to be effective at knocking down 
the levels of target mRNAs in zebrafish , were utilized to selectively decrease the levels 
of zebrafish SMN protein. Knockdown of zebrafish SMN in the embryo resulted in 
defects in axonal outgrowth and pathfinding, mainly in the form of truncated and 
improperly branched motor neuron axons. Other neuronal subtypes were unaffected, 
demonstrating a similar tissue-specific pattern as observed in SMA patients.  
76
 Expression of a human SMN transgene in the morpholino-decreased background 
resulted in partial rescue of the axonal defects, while expression of a pathogenic human 
SMNΔ7 transgene did not, indicating that the axonal defects were due directly to loss of 




neurons, zebrafish smn was specifically knocked down in individual motor neurons. 
Reduction of SMN protein levels in the motor neuron alone was sufficient to reproduce 
the axonal defects observed upon SMN knockdown in the whole organism, indicating 
that other cell types are not involved in SMA disease pathogenesis. However, as the 
invertebrate models of SMA each produced some species-specific effects that are not 
recapitulated in the human disease state, the development of mouse models were required 
in order to gain a more thorough understanding of disease pathogenesis in a mammalian 
system. 
 
SMN in Mus musculus (mouse) 
 
Mouse models have now been developed modeling from the most severe types of 
SMA to more mild forms. As mice have only the single murine smn (mSmn) gene, 
corresponding to human SMN1, homozygous knockout of mSmn results in early 
embryonic lethality 57. Mouse models of SMA are generated by replacing mSmn with a 
pathogenic human transgene. Mice with 1-2 copies of the human SMNΔ7 transgene 
survive up to four days after birth, however they generally show progressive weakness 
and loss of motor neurons by postnatal day 2 56. Mice with eight or more copies of the 
human SMNΔ7 transgene are phenotypically normal, providing strong evidence that 
upregulation of the human SMN2 gene could be therapeutically beneficial.  
Through the use of a severe mouse model of SMA, it was observed that loss of 
muscle function predates motor neuron loss 77. This was explained by the identification of 




show poor terminal arborization and immature acetylcholine receptor clusters, indicative 
of inadequate maturation of the NMJ 78. Defects in the NMJs have also been reported in 
human SMA patients 78, indicating that these mouse model faithfully recapitulate the 
disease pathogenesis of SMA.  
To determine the temporal onset of NMJ defects, McGovern and colleagues 
expressed the HB9:GFP motor neuronal marker in the hSMN2/mSmn-/- mouse model 79, 
to allow visualization of the axonal outgrowth. The gross morphology of the motor 
neurons (MNs) appeared intact, and no defects in axonal pathfinding or branching were 
observed indicating these defects are specific to the zebrafish model of SMA 75. In this 
study, approximately half of the intercostal synapses were shown to be deinnervated, 
however less severe denervation have been observed in human studies 78 as well as in 
other mouse models of SMA.  
One such study was performed by Kong and colleagues, in which they utilized the 
severe hSMN2/SMNΔ7/mSmn-/- mouse model to investigate perturbations at the NMJ 80. 
In this mouse model, the authors found a very low degree of denervation, even late in 
disease progression. Rather, they found that the primary deficiency was functional 
deficits in synaptic transmission, caused by defects at both the pre- and post-synaptic 
sites.  
To determine whether defects due to decreased SMN expression occur cell 
autonomously in a mammalian model of SMA, Gavrilina and colleagues performed 
experiments to determine the spatial need for SMN 81. Utilizing a severe mouse model of 
SMA (hSMN2;mSmn-/-), they expressed SMN in either exclusively in the nervous system 




promoter). Neuronal expression of SMN rescued the phenotype while muscular 
expression did not, agreeing with the zebrafish studies that decreased levels of SMN 
result in cell autonomous degeneration of motor neurons 75.  
 A serious question relevant to the treatment of SMA is the temporal requirement 
for SMN. Or in other words, how late in disease progression can the phenotype be 
rescued? To address this question, Hammond and colleagues created a mouse model with 
inducible alleles of murine Smn 82. The induction of SMN production during early 
gestation could rescue the embryonic lethality seen in these mice, however induction 
during late gestation could not rescue the pups. This strongly suggests that there is a 
window of opportunity for treatment of SMA before the neuronal degeneration and 
consequent downstream defects become unable to be reversed. In theory, this ‘point of no 
return’ would be earlier in life for the Type I patients and later for the milder Type III 
patients.  
Altogether, animal models of SMA have demonstrated that SMN is an 
evolutionarily conserved and essential gene.  SMN is required for pre-mRNA splicing, 
and decreased levels of this protein result in axonal defects in both invertebrate and 
mammalian systems. Mouse models have been the most faithful in replicating disease 
phenotypes, and continue to be useful in therapeutics studies. 
 
The Survival of Motor Neuron Protein: Structure and Function 
 





SMN mRNA and protein are expressed in all tissues of metazoan organisms 83,84, 
indicating that the activity of SMN is essential to cell function. The expression of SMN 
protein is developmentally regulated, with the highest expression levels observed during 
embryogenesis , declining postnatally to low levels in most adult tissues . 
However, some tissues, including the CNS, the kidney and liver retain high levels of 
SMN expression into adulthood , suggesting they may be more dependent on SMN 
activity. A study comparing the levels of SMN protein in 
85-87 84,85
42
Type I patients compared to 
phenotypically normal individuals found that SMN protein levels are reduced between 
96-99% in spinal cords 42, with a more moderate difference (70-90%) in fibroblasts, 
suggesting there may be cell type-specific pathways regulating SMN protein levels, and 
these pathways may be differentially regulated in the disease state. 
SMN has been shown to be localized to the nucleus and cytoplasm in all cell 
types , although the fraction localizing to each region varies by cell type. Within the 
nucleus of some tissues, SMN can be found concentrated in punctate structures termed 
gems. The term gems stands for gemini of coiled bodies
88
, as the two structures are often 
found in close proximity 88,89. Coiled bodies, also known as Cajal bodies, are nuclear sub-
organelles involved in assembly of components of the RNA splicing machinery 90. The 
interaction between gems and Cajal bodies appears to be developmentally regulated as 
the two structures do not colocalize strongly in fetal tissues, however this interaction 
increases with age, with nearly complete colocalization in adult tissues 91. This proximity 
first suggested a role for SMN in RNA splicing.  
Since the discovery of gems in 1996, a great deal of progress has been made 




splicing. SMN has been identified to be a necessary component for the formation of gems, 
as RNAi knockdown of SMN in HeLa cells results in complete loss of gems  and the 
number of gems has been demonstrated to be correlated with SMN protein levels and 
disease severity . Although gems are seen in all fetal tissues , they appear to be 
disassembled in some cell types upon maturation. Adult tissues of humans, pigs and 
rabbits were stained for SMN, however gems were not observed in blood vessels, cardiac 
and smooth muscle, stomach or spleen across all species 
92
42 91
89. This suggests that gems are 
not absolutely required for formation of the pre-mRNA splicing machinery, and may 
serve as repository for excess spliceosomal assembly proteins. 
 
SMN domain structure and functions 
 
Human SMN mRNA contains eight exons (1, 2A, 2B and 3-7), and is translated 
into a 294 amino acid, 38kDa protein with no significant homology to other proteins. The 
tertiary structure of the SMN protein is poorly understood, with the exception of the 
Tudor domain in exon 3, which has been crystallized . Notable secondary structures 
within the SMN protein include the lysine-rich (K-rich) exons 2A and 2B, the extended 
proline-rich domain (P-rich) in exons 5 and 6 and the tyrosine/glycine rich region (YG 
box) in the C-terminal end of exon 6 (Figure ii). 
93,94
The Tudor domain in exon 3 has been identified as the Sm protein binding region 
. The missense mutations E134K and W92S, which have been identified in SMA 
patients lacking the more common homozygous SMN1 deletion pattern, reside within the 







Figure ii. SMN protein domain architecture.  
SMN protein is 294 amino acids long, and the relative exon sizes are diagrammed with 
the exon number within. Identified protein domains and an abbreviated list of SMN 





complex to bind Sm proteins 70,95. The E134K mutation, as well as the I116F and Q136E 
mutations also identified within the Tudor domain, have been shown to negatively affect 
U snRNP assembly 69,96,97. Although these SMA-causing mutations suggest that the 
primary cause of SMA is a defect in spliceosome assembly, a hypothesis with several 
proponents , there exist other SMA-causing mutations within this domain that do 
not affect Sm protein binding  or snRNP assembly . At this time it is unclear how 
strong a role the Tudor domain plays in the development of SMA, and mutations 
resulting in SMA have been identified in other domains as well. 
69,98-100
70 96
The SMA missense mutations D30N and D44V have been identified in the K-rich 
exon 2A 70. Together with exon 2B, this region is required for binding Gemin2/SIP1, a 
major component of the U snRNP-assembling SMN complex 72,101. However, these 
mutations do not show a defect in SMN binding to Gemin2 70, nor do they significantly 
affect Sm protein binding or snRNP assembly 70,96, indicating that this region may have 
additional functions that have yet to be identified. 
Animal model studies have demonstrated that these mutant forms of SMN are not 
functional alone, as they cannot rescue survival in the absence of a human SMN2 
transgene 102. Instead, these partially functional mutants require a limiting amount of 
wild-type SMN in order to assemble snRNPs in vitro, as demonstrated by 
complementation studies 98; in vivo the small amount of wild type SMN would be 
provided by the SMN2 gene. This suggests that SMN functions as an oligomer, and that 
the heteromers made up of the mutant and wild type SMN proteins restore sufficient 
function for survival of the organism, but not enough to prevent degeneration of the 




including observed oligomerization of SMN 103,104 and gel filtration studies which have 
estimated that SMN is stably organized as an octomer .  105
The C-terminal region of SMN has been shown to be important for self-
oligomerization. Mutations in the C-terminal exons 6 and 7 generally affect the ability of 
SMN to self-oligomerize, and the YG box in exon 6 has been shown to be vital for this 
self-association .  The severe oligomerization defects associated with the SMA 
mutations Y272C and G279C/V significantly affect SMN activity, as demonstrated by 
decreased U snRNP assembly 
68
96,103,104,106,107 These mutants also result in severe Type I 
SMA in patients with one to two copies of SMN2. The exon 7-deleted SMN protein 
(SMNΔ7) mainly produced by SMN2 also falls into this category, as it demonstrates a 
reduced capability for self-oligomerization 103, making it unable to compensate for the 
decreased levels of full-length SMN due to homozygous SMN1 deletion. 
 
SMN interacting partners 
 
In addition to self-association, SMN has been shown to interact with a diverse 
array of proteins involved in many cellular functions, such as apoptosis 108-110, assembly 
of U snRNPs 72,101, and axonal transport of mRNAs 111,112. The ability of SMN to interact 
with both the RNA and protein components of many RNP complexes have led some to 
suggest it is an assemblyosome for RNPs 113,114. The most well-defined RNP assembly 
function of SMN is its construction of the U snRNPs, which is performed by the 





The SMN Complex 
 
The SMN complex is responsible for assembly, fidelity and transport of uridine-
rich small nuclear ribonucleoproteins (U snRNPs) 115,116, which in part make up the 
mammalian spliceosome. U snRNPs are composed of a ring of seven Smith-class (Sm) 
proteins and a unique small nuclear RNA (snRNA) . The snRNA is responsible for 
recognition of their cognate splice sites on pre-mRNAs . The SMN complex has been 
shown to be necessary and sufficient for assembly of U snRNPs in vitro, and prevents the 




The SMN complex consists of multiple units of SMN in a large macromolecular 
complex with nine additional proteins: Gemin2/SIP1, Gemin3/DP103, Gemin4, 
Gemin5/p175, Gemin6, Gemin7, Gemin8 and UNR-interacting protein (UNRIP) 101,120-126. 
Gemin3 and 5 contain notable protein motifs. Gemin3 contains the Asp-Glu-Ala-Asp 
DEAD–box motif 120, and has been demonstrated to have ATP-dependent RNA helicase 
activity 127, which may be required for the SMN complex’s assembly of RNPs. Gemin5 
contains 13 WD repeats 122, which may be involved in scaffolding of the many protein-
protein interactions directed by the SMN complex. 
The SMN complex is highly stable, remaining associated even in stringent in vitro 
conditions 113. Gemins 2, 3, 5 and 7 bind SMN directly, while Gemin4 binds via Gemin3 
and Gemin6 binds via Gemin7. The Gemins colocalize with SMN both in the cytoplasm 
and in nuclear gems 101,120,122,124. The SMN complex assembles snRNPs in the cytoplasm, 
however the Sm proteins must first be dimethylated by the protein arginine 




132. The dimethylarginine-modified Sm proteins are then transferred to the SMN complex, 
which mediates their proper assembly onto their respective snRNAs 72,101,133 bound by 
Gemin5 134. The 7-methylguanosine cap of the snRNA is then hypermethylated by 
trimethylguanosine synthetase 1 (TGS1) 135, and several 3’ nucleotides on the 3’ termini 
of the snRNPs are trimmed, which appear to increase the import kinetics of the snRNPs 
136. The snRNP-SMN complex is then imported into the nucleus via its interactions with 
snurportin 137 and importin-β 138. Within the nucleus, the SMN complex as well as the 
snRNPs are concentrated within the nuclear sub-organelles called Cajal bodies 139, where 
the snRNPs undergo further maturation 140.  
Lack of functional SMN complex has been proposed to be the cause of SMA 98,99, 
however many have voiced concerns over the ability of a ubiquitous and essential 
function to mediate motor neuron-specific cell death. Animal models of SMA have both 
supported 98,99 and oppposed 107,141 the hypothesis that decreased snRNP assembly is the 
cause of SMA, however alternative hypotheses have begun to gain favor after the 
identification of additional, neuron-specific SMN-protein complexes. 
 
SMN interacts with hnRNPQ/R and -actin mRNA 
 
 A yeast two-hybrid study identified the heterogeneous nuclear ribonucleoproteins 
(hnRNP) R and Q as binding partners for SMN 142. The C-terminal ends of the hnRNPs R 
and Q are likely required for SMN protein binding, as they contain arginine-glycine-
glycine (RGG) domains which have been shown to be important for Sm protein binding 




various SMA mutants E134K, S262I, T274I, Y272C, G279V, Δexon7, Δexon5, 
Δexon5+7, indicating this complex could be relevant to the disease state. Additionally, 
hnRNP R was demonstrated to be expressed most prominently in motor neurons, rather 
than other neuronal subtypes, such as sensory peripheral nerve and Schwann cells 142, 
suggesting it may have motor neuron-specific functions.  Both hnRNP R and Q were 
determined to be developmentally regulated in mouse spinal cord, with high expression 
levels during late embryogenesis and significantly decreased postnatal levels, a temporal 
expression pattern similar to SMN. hnRNP R colocalized with SMN in the cytoplasm and 
axons of mouse spinal cord sections and embryonic motor neurons. Although it was 
present in the nucleus, it did not colocalize with nuclear SMN, suggesting that hnRNP R 
binding to SMN is independent of the snRNP assembly functions of the SMN complex. 
Due to difficulties with the antibody against hnRNP Q, only colocalization between 
hnRNP R and SMN could be determined in this study. 
 The complex of SMN bound to hnRNP R was later demonstrated to have vital 
neuronal functions as overexpression of either SMN or hnRNP R stimulated neurite 
outgrowth in neuronal-like PC12 cells in culture 144. Neurite length was not affected upon 
expression of an hnRNP R mutant lacking the SMN interaction domain, indicating that 
the interaction of SMN and hnRNP R is necessary to mediate this function in the axon. 
Next, the authors tested the importance of the SMN-hnRNP R heterocomplex in motor 
neurons isolated from a severe mouse model of SMA 56. These SMA motor neurons 
demonstrate reduced axonal outgrowth in culture, with smaller growth cones and 
decreased levels of -actin mRNA and protein within the growth cone. hnRNP R 




mRNA via a 54 nucleotide zipcode sequence within its 3’ UTR. This zipcode has been 
shown to be both necessary and sufficient for peripheral localization of -actin mRNA 
145.  
Knockdown of hnRNP R in isolated mouse motor neurons demonstrated a similar 
defect in axonal outgrowth and -actin mRNA translocation as was observed in the 
motor neurons isolated from the SMA model mice 111, suggesting that a SMN-hnRNP R 
heterocomplex is responsible for transporting -actin mRNA to the growth cones. This 
model also suggest that defects in this function, via decreased levels of SMN or hnRNP 
R, lead to reduced axonal outgrowth and defects in presynaptic maturation 111. 
Deficiencies in pre-synaptic differentiation have been observed in SMA mouse models 
78,146, strongly suggesting that this pathway may be affected in SMA patients. 
 
SMN and profilin 
 
Another SMN heterocomplex which has been shown to have neuron-specific 
effects is the SMN-profilin complex, providing another alternative hypothesis for the 
motor neuron-specific phenotype observed in SMA patients. The polyproline (P-rich) 
region in exons 5 and 6 of SMN have been shown to bind profilins , and colocalization 
has been observed in the growth cones of cultured PC12 cells . Profilins are actin-
binding proteins which can regulate actin polymerization dynamics by sequestering -
actin monomers, preventing them from being added to growing actin microfilaments . 
BIAcore studies indicated a strong, specific interaction between SMN and profilin IIa , 









abolished when pathogenic mutants of SMN were utilized in the study. RNAi studies in 
PC12 cells demonstrated that reducing SMN protein levels resulted in increased 
expression of profilin IIa, and together with decreased availability of SMN, leads to 
increased formation of the profilin IIa/RhoA/ROCK complex . 151
Activation of the Rho-associated kinase 152 by the small GTPase RhoA is 
involved in cytoskeleton-mediated motility, polarity and gene expression 153. These 
effects are mediated by phosphorylation of myosin light chain (MLC) which inhibits 
neuronal outgrowth and differentiation 154. Regulation of neuronal outgrowth by ROCK 
has been shown to be mediated in part by profilin IIa’s control of actin polymerization 155. 
Therefore, increased formation of the profilin IIa/RhoA/ROCK complex can result in 
inhibition of neuritogenesis, suggesting an alternative mechanism for the decreased 
axonal outgrowth observed in motor neurons isolated from SMA model mice 142. 
 
The possible role of actin dynamics in Spinal Muscular Atrophy 
 
 The studies identifying profilin IIa and hnRNP R as SMN binding partners 
suggested an important role for SMN in actin dynamics and regulation of the 
cytoskeleton. A study searching for SMA-modifying genes in discordant SMA families, 
(families with siblings who have the same genotype but display different severity of 
phenotypes) demonstrated 3-fold higher expression levels of the actin-bundling protein 
plastin 3 (PLS3/T-plastin) in unaffected individuals versus their affected counterparts 156. 
The unaffected SMN1-deleted siblings who expressed increased levels of PLS3 also had 




vital for axon outgrowth and pathfinding 157. These findings were validated in motor 
neurons isolated from an SMA model mouse, where overexpression of PLS3 rescued the 
axonal outgrowth defects of the SMN-deficient neurons, albeit not completely 156. 
However, another study utilizing an SMA mouse model demonstrated that increasing the 
levels of PLS3 could not rescue the SMA phenotype, even upon concomitant knockdown 
of profilin IIa, suggesting that additional factors may be involved in the dysregulation of 
actin dynamics in the disease state 158. However, as SMN and PLS3 were found to be 
colocalized in the axons and growth cones of wild-type mouse motor neurons, this study 
identifies yet another SMN binding protein involved in the regulation of actin dynamics.  
 The importance of the cytoskeleton in SMN-deficient motor neurons was 
highlighted in a recent study which demonstrated significantly increased survival in an 
intermediate mouse model of SMA 158 treated with the ROCK inhibitor Y-27632 159. The 
treated mice had improved motility and neuromuscular junction innervation, although 
surprisingly Y-27632 did not rescue the motor neuron loss seen in this mouse model. 
Additionally, treatment with the ROCK inhibitor in a severe mouse model of SMA 
showed no rescue, suggesting that the axonal defects in this model are either too multi-
faceted or too severe to be compensated by inhibition of ROCK alone. However, this 
study strongly supports an involvement of cytoskeletal dynamics in the pathogenesis of 
SMA.  
 





SMN has been demonstrated to be highly expressed in neuronal tissues in vivo 42, 
and has been shown to localized to neurites and growth cones in neuronal cells in culture 
148. Within the CNS, SMN gene expression was found to be selectively enriched in 
specific cell populations. In the spinal cord, in situ hybridization revealed strong staining 
in the ventral horn, with little staining in the dorsal horn. Interestingly, SMN protein 
expression was found most highly expressed in the cytoplasm of neurons in the spinal 
cord and brain , as opposed to the strong, punctate nuclear staining generally observed 
in cells in culture. The authors propose that the difference in the localization of SMN is 
due to fully-differentiated, post-mitotic nature of the cells being studied within the tissues. 
However, other studies have reported gem-like nuclear staining within post-mitotic motor 
neurons . SMN protein expression was reported to be highly abundant in the neurons 
of the deep cerebellar nuclei, pallidal neurons in the basal ganglia, layer V pyramidal 
neurons of the neocortex and motor neurons in the brainstem and spinal cord . Defects 
in the development of these brain regions have been recently observed in a mouse model 






Neuronal defects observed in animal models of SMA 
 
SMN had also been proposed to have important functions in axonal outgrowth 
and formation and maturation of the neuromuscular junction (NMJ). Several animal 
models of SMA have been utilized to gain further understanding of SMN’s role in 
neurons. Knockdown of Smn in zebrafish results in defects specifically in motor neurons, 




embryonic lethal, to better understand the developmental and long-term effects of 
decreased SMN protein levels, SMN2 (hSMN2) transgene 56,162. These mice produce 
~10% of the amount of SMN protein produced by wild-type animals, and display severe 
motor defects. Motor neurons extracted from these SMA model mice display reduced 
axonal outgrowth as well as decreased growth cone size , however these growth 
defects are not observed in vivo . This mouse model displays electrophysiological 
abnormalities, and show defects in calcium channel clustering of the subtypes Cav2.1 and 
Cav2.2 . However, expression of the calcium channel subtypes found to be irregularly 
clustered in SMA is not restricted to motor neurons. These channels are also expressed in 
many other CNS neuronal populations, and it is therefore unclear why the altered, 




Additional deformities of the neuromuscular junction (NMJ) are evident in mouse 
models. Aberrant neurofilament (NF) accumulation has been repeatedly observed, both in 
the axons and in the NMJ . Decreased complexity of the NMJ morphology, 
including reduced NMJ folding and arborization, is consistent with the lack of maturation 
of the NMJ’s suggested by improper calcium channel clustering . Denervation, as 
defined by a NMJ unoccupied by a motor neuron, is also a common finding. The extent 
of denervation generally correlates with the degree of severity in the SMA mouse models 
, although one study found no pre-synaptic abnormalities in pre- or post-synapses 
. A recent study in the severe Smn ;SMN2  mouse model also found mitochondria 
with disturbed christae on both the pre- and post-synaptic sides of the NMJ, as well as 









observed in the diaphragm, a muscle affected in this animal model, but not in the soleus, 
a muscle mostly spared in this model. 
Defects in neuromuscular junction morphology often result in altered 
neurotransmission, which is seen in both the most severe  and milder SMA mouse 
models . These defects range from reduced quantal content to facilitation, though not all 
defects are observed across all the SMA mouse models. A reduction in the synaptic 
vesicle (SV) quantal content (amount of neurotransmitter per vesicle) was observed in the 
SMN2;SMNΔ7;Smn  severe SMA mouse model , and to a more modest degree in the 
SMNΔ7;Smn  mouse model  . The severe SMA mouse model also demonstrated 
additional SV defects, such as reduced SV release probability and decreased SV density, 





+/+ -/- +/+ did not confirm this 
phenotype . The milder mouse model demonstrated intermittent neurotransmission 
failure, although in this model innervation was retained well into the disease course. The 
neurotransmission failure and reduced SV release probability have been proposed to be a 
result of the defects in Ca  channel clustering. The results from these animal models 
demonstrate a vital role for SMN in motor neurons, however the question remains as to 
the exact nature of SMN’s function in the axon, and how the lack of this activity results 




How can decreased activity of a ubiquitous protein result in a tissue-specific disease? 
 
The question of how a defect in a ubiquitous housekeeping gene could result in 




times, by many researchers. However, SMA is not alone in this category, as several other 
ubiquitously expressed genes have been implicated in CNS disorders. These genes 
include spastin, aminoacyl tRNA synthetases and parkin. Spastin (SPG4) is an AAA 
family ATPase with a role in regulating microtubule stability 168. Mutations in spastin 
cause the most common form of autosomal dominant hereditary spastic paraplegia (AD-
HSP) 168. AD-HSP is a neurodegenerative disease characterized by spasticity and 
weakness in the lower extremities and degeneration of axons 169.  
Aminoacyl tRNA synthetases (ARSs) are responsible for loading tRNAs with 
their correct amino acid during translation, however mutations in these essential proteins 
lead to a multitude of diseases including the neurodegenerative disorders Charcot-Marie-
Tooth disease type 2D and Leukoencephalopathy 170. Rare familial forms of Parkinson’s 
have been connected to pathogenic mutations in parkin (PARK2), a subunit of an E3 
ubiquitin ligase complex . Each of these proteins, including SMN, are expressed 
ubiquitously in all tissues.  
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In general, three mechanisms can be conceived in which impairment in a 
ubiquitous protein could result in a tissue-specific disease. The simplest mechanism 
would be that the tissue in question is more sensitive to alterations in the levels of activity 
of the ubiquitous protein. Alternatively, it is possible that the pathway(s) regulated by the 
disease-protein are different in the specific cell type. Lastly, the protein of interest may 
have additional tissue-specific functions, due to e.g. tissue-specific expression of a 
binding partner, or tissue-specific splicing of the disease gene.  
The most conservative hypothesis proposed suggests that motor neurons are more 




biogenesis leads to defects in splicing resulting in decreased levels of proteins required 
for motor neuron homeostasis . Alternatively, as motor neurons have extremely long 
processes, the discovery that SMN is involved in axonal transport of RNP particles lead 
to the hypothesis that the motor neuron degeneration is due to deficient local synthesis of 
proteins required for axonal outgrowth and maintenance .  
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To round out the potential hypotheses, a tissue-specific splicing isoform of SMN 
was identified by Setola et al., however their findings remain controversial to date. The 
authors reported the discovery of an alternatively spliced isoform of SMN1 which is 
selectively expressed in motor neurons 172. This isoform, termed axonal-SMN or a-SMN, 
retains intron 3 in the spliced transcript. However, as intron 3 contains an in-frame stop 
codon, a-SMN is significantly smaller than full-length SMN, and was identified as a 
~20kDa band, utilizing antibodies developed by the lab. Additionally, a-SMN was 
reported to be expressed solely in the axons of motor neurons within the spinal cord, and 
to be maximally expressed during initial development of the neuromuscular system. 
Transfection of a-SMN into NSC-34, a mouse motor neuron-like cell line, stimulated 
production of filipodia-like extensions. These extensions developed into a single, long 
axon by 72 hours post-transfection, similar to what is seen in motor neurons. In 
comparison, transfection of full-length SMN had no effect. The authors suggest that a-
SMN has a vital role in axonogenesis, a neuronal function which has been shown to be 
impaired in SMA animal models. However, SMA patients have been identified with 
mutations in exon 6, which is not included in this isoform 106. Therefore, although it is 
tempting to ascribe a tissue-specific disease to tissue-specific expression of an isoform of 





Neuromuscular disorders with similarities to SMA 
 
A rare, yet interesting finding was the report of a single SMA patient with an 
increase in serum anti-acetylcholine receptor antibodies (α-AChR-Ab). The presence of 
α-AChR-Ab in the blood is usually an indicator of the neuromuscular disorder 
myasthenia gravis (MG). MG is characterized by muscle fatigability and predominantly 
affects the muscles of the eyes and limbs, as well as those involved in swallowing or 
breathing 173. MG is an autoimmune disease caused by auto-antibodies against the 
nicotinic acetylcholine receptor (nAChR) or muscle specific kinase (MuSK). These 
proteins are found in the neuromuscular junction (NMJ) and have important roles in 
neurotransmission. Although the patient’s diagnosis was confirmed as SMA, not MG, the 
identification of auto-antibodies in the blood suggested that there may be sufficient 
trauma or degeneration at the neuromuscular junction to hyper-activate the immune 
system. 
A neuromuscular disorder closely related to MG is Lambert-Eaton myasthenic 
syndrome (LEMS). LEMS is of special interest, as the symptoms of LEMS are strikingly 
similar to those of SMA. In both disorders, patients develop progressive weakness of the 
proximal muscles of the limbs, with facial and respiratory muscles usually remaining 
unaffected. LEMS, however, is an autoimmune disorder usually identified by the 
presence of auto-antibodies against the neuromuscular junction proteins P/Q-type voltage 
gated calcium channels (VGCCs), synaptotagmin 1 (Syt1) or the M1-type presynaptic 




with the P/Q-type VGCCs, suggesting a common mechanism. The appearance of these 
auto-antibodies is usually temporally associated with malignant neoplasms, most often 
small cell lung carcinoma, in which the tumor cells express one or more of these proteins 
175. The immune response against the neoplastic cells is speculated to result in the NMJ 
proteins becoming antigenic. Auto-antibodies against any of the three proteins (VGCCs, 
Syt1 or M1-AChR) are realeased into the bloodstream, bind to protein at the NMJ, 
resulting in impaired acetylcholine signaling and consequent muscle weakness.  
The involvement of Syt1 in LEMS was of interest, as mice bearing a homozygous 
loss of function mutation of Syt1 or modeling a severe form of SMA are phenotypically 
similar 56,176. Both mouse models are phenotypically indistinguishable from their normal 
littermates at birth, but demonstrate progressive skeletal muscle weakness, poor suckling 
and abnormal synaptic vesicle release prior to dying within 48 hours after birth. The 
similarity in phenotype could suggest an association between SMN and Syt1. In fact, 
there is the possibility of a physical interaction between SMN and Syt1, as they share a 
binding partner in hnRNP Q (also known as SYN-CRIP, standing for synaptotagmin-
binding cytoplasmic RNA interacting protein). Syt1 and hnRNP Q/SYNCRIP have been 
shown to interact in vitro 177. 
Syt1 is an abundant, neuron-specific synaptic vesicle transmembrane protein 
whose N-terminal region cycles between vesicular and extracellular during synaptic 
vesicle fusion 178. Syt1 is believed to be a calcium sensor for regulation of synchronous 
neurotransmitter release via synaptic vesicle (SV) fusion 179, as mutations which 
modulate binding to Ca  ions directly affect the Ca -dependent SV release probability 2+ 2+ 




activity of Syt1 may be relevant to SMA, as several researchers have demonstrated 
defects in neurotransmission in SMA animal models  although there have been 
conflicting reports stating that decreased levels of SMN have no effect on 
electrophysiological activity of motor neurons . Future studies investigating the 
potential interaction between SMN and proteins involved in synaptic vesicle release and 





Axonal defects in animal models of SMA 
 
It has been suggested that the motor neuron degeneration observed in SMN is due 
to decreased activity of its housekeeping function: assembly of the spliceosome for pre-
mRNA splicing. Jablonka et al. investigated the importance of splicing activity for motor 
neuron health by creating a double heterozygous mouse model for Smn and Gemin2 . 
SMN and Gemin2 are required subunits for the macromolecular complex, termed the 
SMN complex, which is the assemblyosome for the spliceosomal uridine-rich small 
nuclear ribonucleoproteins (U snRNPs). In the double heterozygote mouse model Smn
;Gemin2 , spliceosome assembly was further decreased compared to the Smn  mice, as 
determined by a reduction in the nuclear pool of Sm proteins. The Smn ;Gemin2  mice 
also demonstrated an 34% decrease in the number of lumbar motor neurons, in 
comparison to the 9% reduction observed in the single heterozygous Smn  mice. This 









neurons are extremely sensitive to reductions in the level of spliceosomal activity, and 
that defects in splicing can result in the loss of motor neurons observed in SMA patients. 
In support of the hypothesis that SMA pathogenesis resulted from deficient 
spliceosomal activity, Gabanella et al. demonstrated that SMA severity correlated with 
snRNP assembly potential . The authors show a preferential decrease in the assembly of 
a subset of U snRNPs, especially U11 snRNP, indicating that the decrease in SMN does 
not affect all U snRNPs uniformly. The U11 snRNP is part of the minor spliceosome, 
which is responsible for splicing between four hundred and seven hundred genes in the 
human genome . This small subset of genes may include protein products vital to 
the health of motor neurons, and could contribute to SMA disease pathogenesis.  
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In another study of snRNP activity in a SMA mouse model, Workman et al. 
demonstrated that expression of an SMN isoform containing a missense mutation seen in 
SMA patients, SMN(A111G), can rescue a hSMN2 ;mSmn  severe SMA mouse model 
. The SMN(A111G) allele retains the ability to assemble U snRNPs. Its ability to 
complement hSMN  correlates with an increase in the level of snRNP activity in the 





To directly assess the role of U snRNPs in motor neurodegeneration, Winkler et 
al. knocked down Smn in Danio Rerio (zebrafish) and Xenopus laevis (African clawed 
frog) and demonstrated defects in U snRNP assembly and degeneration of motor axons, 
comparable to the pathology seen in SMA  (Figure iii). Similar results were observed 
upon knockdown of Gemin2 and 
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Figure iii. SMN knockdown results in axonal pathfinding defects in zebrafish. 
Lateral views of zebrafish trunk with stained motor neurons. (A)  Motor neuron 
phenotype in zebrafish injected with a control morpholino versus, (B) injected with a 
morpholino against smn mRNA. Arrowheads indicate trunctated or abnormally branched 






Smn or Gemin2 knockdown could be rescued by injection of purified U snRNPs into the 
Smn- or Gemin2-deficient embryos, suggesting that the motor neuron defects observed 
upon knockdown of SMN resulted directly from decreased splicing efficiency. 
Despite the strong evidence linking deficiencies in snRNP activity to SMA 
pathogenesis, several other studies have failed to find any correlation between snRNPs 
and SMN’s function in axons. Carrel et al. utilized morpholinos, nuclease-resistant 
phosphorodiamidate antisense oligomers, to knock down the levels of Smn in zebrafish 
. Reducing the levels of SMN protein in zebrafish results in motor neuron-specific 
defects, such as truncated axons and irregular axonal branching . Various human SMN 
mRNAs, including wild-type and SMA-causing mutants, were then co-injected in order 
to determine their effects on the axonal defects observed upon Smn knockdown. 
Although several of these mutant SMN proteins retain the ability to assemble snRNPs, 
only wild-type SMN was able to rescue the axonal outgrowth defects, suggesting that 
motor neuron-relevant function of SMN is independent of snRNP biogenesis.   
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McWhorter et al. performed a similar examination to investigate the role of 
Gemin2 in motor neurons . The authors knocked down Gemin2 in zebrafish, however, 
while knock down of Gemin2 resulted in abnormal development of the zebrafish embryos, 
the motor neuron axons were unaffected. Motor neuron-specific knockdown of Gemin2
141
 
additionally had no effect on motor neuron morphology or function.  The authors 
conclude that since Gemin2 is required for proper snRNP biogenesis and knockdown of 
Gemin2 has no effect on motor neurons, the neuronal defects seen upon Smn knockdown 




 Splicing defects have also been investigated in mouse models of SMA. Baumer, 
et al. investigated whether SMN decrease leads to splicing defects early in the disease 
course, which would suggest a direct role in disease pathogenesis. Utilizing exon arrays, 
the authors demonstrated that the SMA model mice show progressive alterations in 
splicing, but these defects only become readily apparent late in the disease course, 
suggesting that alternative splicing events are unlikely to be causative for degeneration of 
the motor neurons 189. However, as SMA model mice have been shown to be selectively 
deficient in components of the minor spliceosome, it cannot be ruled out that defects in 
the splicing of a small number of genes, while going unnoticed in this screen, result in 
SMA disease pathogenesis. 
 Despite our advances in understanding the disease pathogenesis of SMA utilizing 
animal models, it remains unclear how reduced levels of SMN protein result in motor 
neuron-specific degeneration (Figure iv). Previous studies have shed light on several 
potential neuron-specific functions of SMN, however it has yet to be conclusively shown 
whether any of the proposed mechanisms, or a yet unidentified function, is the causative 
agent in SMA. 
 
Current state of small molecule therapeutics for SMA 
 
Small molecule screening has proven indispensible for the identification of 
compounds inhibiting enzymes or cellular functions of interest. These bioactive 
compounds have provided us with tools to dissect the molecular mechanisms underlying 





Figure iv. The pathogenic events occurring in motor neurons in SMA. 
The homozygous loss of the SMN1 gene results in neurons being forced to rely on the 
decreased levels of functional SMN protein produced by the SMN2gene. This results in a 
myriad of negative effects on motor neurons, included defects in U snRNP biogenesis, 
axonal pathfinding and synaptic vesicle release. Each of these could be the root cause of 
the motor neuron degeneration observed in Spinal Muscular Atrophy. Image reproduced 




into extremely valuable drugs. Drugs such as AZT (azidothymidine), the anti-retroviral 
that changed HIV infection from a fatal disease to a manageable chronic condition in the 
late 1980’s 191, are important inhibitors that were discovered through high-throughput 
small molecule screens.  
However, not all cellular functions or diseases of interest are best addressed by an 
inhibitor. In certain cases, an activator of an enzyme or cellular process could provide 
more information on the process being studied, or perform an action necessary for a 
diseased organism to reestablish homeostasis. Small molecule activators can be 
categorized into one of three groups. The first and most common type of activator is the 
‘inhibitor of an inhibitor’, which generally follow the adage ‘the enemy of my enemy is 
my friend’. Compounds that fall into this category include many of the small molecules 
that induce cell death pathways, such as the classical activators of apoptosis: 
camptothecin (topoisomerase I inhibitor)192, staurosporine (broad spectrum kinase 
inhibitor)193 and cycloheximide (protein synthesis inhibitor)194.   
The second, and more rare, type of activator could be considered an ‘enabler’. 
One mechanism of actions for these molecules is to bind allosterically to their target 
enzyme, lowering the activation energy of the enzymatic reaction. Examples of this type 
of activator mainly include endogenous small molecule ligands, such as the secondary 
metabolite inositol hexakisphosphate, an activator of RTX cysteine proteases 195. 
However, exogenous ‘enablers’ have also been identified, such as the non-ligand small 
molecule which was recently identified in a high-throughput screen as an activator of 




auto-proteolytic processing of pro-caspase 3 to the active form, caspase 3, ‘enabling’ the 
activation of downstream pro-apoptotic pathways.  
 A third type of activator is an ‘upregulator’. This type of compound increases the 
intracellular levels of a target protein or proteins. The advantage of this type of activator 
is that it is protein-class independent. While the activity of most inhibitors and allosteric 
activators are restricted to proteins with enzymatic activity and/or binding pockets for 
endogenous ligands, an ‘upregulator’ could in theory increase the activity, via an increase 
in intracellular level, of any class of protein. Spinal Muscular Atrophy exemplifies the 
type of disease in which an upregulator could be of great use, as it is caused by decreased 
levels of a single protein, Survival of Motor Neuron (SMN) 24. Despite years of research, 
attempts at small molecule modulation of the pathways affected by decreased levels of 
SMN protein have not proven fruitful. The complexities of the neuronal system, and the 
difficulties of studying the system in whole organisms, have limited the understanding of 
the mechanisms resulting in disease pathogenesis. Without understanding the pathways 
being affected, the only option available for therapeutic intervention is to increase the 
concentration of the affected protein.  
There has been a strong drive to discover small molecule upregulators for SMA 
since the genetic basis of the disease was identified in 1995 24. In SMA, the survival of 
motor neuron 1 (SMN1) gene is mutated or deleted. However, there exists a nearly 
identical gene copy, the SMN2 gene, which produces SMN protein, albeit at significantly 
lowers levels than SMN1, due to alternative splicing 41. The existence of the gene copy 
opens up new avenues for pharmaceutical intervention not available in most genetic 




a drug that increased the amount of full-length SMN protein produced by the smn2 gene 
has interested researchers and pharmaceutical companies alike for over a decade.  
Several pharmaceutical companies have become involved in efforts to identify 
and develop potential therapeutics for SMA. In conjunction with the Families of Spinal 
Muscular Atrophy (FSMA) Foundation, Aurora Biosciences (now Vertex 
Pharmaceuticals) participated in the high-throughput screen which identified the 
quinazoline backbone as an upregulator of the SMN2 promoter 197. The structure-activity 
relationship 31 and medicinal chemistry required to improve the potency and efficacy of 
the compound class to a level where therapeutic testing would be feasible were 
performed in partnership with deCODE Genetics (Reykjavik, Iceland) 198. The clinical 
candidate resulting from the SAR received Orphan Drug Designation from the FDA and 
was licensed to Repligen Corporation (Waltham, MA) for human trials 
(http://www.repligen.com/products/pipeline/rgsma), providing hope for families affected 
by this devastating disease. In addition to the quinazoline program, FSMA has partnered 
with Paratek Pharmaceuticals (Boston, MA) to develop non-toxic analogs of Aclarubicin 
A , which was identified as a modulator of SMN2 splicing in 2001 
(http://www.paratekpharm.com/pt_tet_tc.html) 199.  
 
HDAC inhibitors in SMA therapy 
 
Histone deacetylase (HDAC) inhibitors were the first small molecule 
pharmaceuticals identified to affect the levels of SMN protein in patient cells. HDAC 




the ε-amino of lysines in the amino terminal tails of histones 200. The histone substrates of 
the HDAC enzymes make up the nucleosomes around which the genomic DNA is 
wrapped. Addition of an acetyl group onto a lysine neutralizes the positive charge of the 
residue. This diminishes the interaction of the positively charged lysine groups with the 
negatively charged DNA, resulting in decreased packing density of the nucleosomes 201. 
This ‘relaxation’ provides access for the gene transcription machinery to the DNA and is 
generally associated with increased gene transcription 202,203. Histone acetylase 8 enzymes 
perform antagonizing functions, utilizing acetyl-coenzyme A to transfer acetyl groups 
onto the N-terminal tails of the lysines, resulting in condensation of the DNA and 
reduced gene transcription. 200 
 Therefore, small molecule inhibition of HDAC enzymes results in globally 
decreased levels of histone acetylation as well as decreased chromatin condensation. This 
has been shown to increase expression of approximately 2% of the genome, or 
approximately 400-500 gene products 203. In addition to its effects on gene transcription, 
HDAC enzymes can cleave acetyl groups from non-histone proteins as well, modulating 
their level of activity. Non-histone substrates identified for HDAC’s include transcription 
factors 204, alpha-tubulin 205,206, signaling regulators and metabolic proteins 207. Due to the 
ability of HDAC enzymes to alter the activity of a wide range of substrates, inhibitors of 
these enzymes have been utilized for the treatment of a wide range of disorders, from 
psychiatric conditions such as epilepsy  to treatments for various cancers .  208,209 152,210
 In 2001, Chang et al. identified sodium butyrate, a simple aliphatic acid known to 
inhibit HDAC enzymes, as a compound able to affect the splicing of the SMN2 gene in 




Treatment with sodium butyrate significantly increased the ratio of SMN transcripts 
containing exon 7 to those lacking exon 7. Western blots of the sodium butyrate-treated 
SMA lymphoid cell lines showed an approximately 130-150% increase in SMN protein 
level. To determine the effect on an SMA mouse model, mice models of Type II and 
Type III SMA were administered sodium butyrate ad libitum in drinking water for 1-12 
weeks or left untreated as controls. The treated group survived significantly longer than 
the untreated group; treatment increased the mean lifespan from 15.5 days in the 
untreated group to 21.7 days in the sodium butyrate treated group (range: 13-20 days for 
untreated, 14-30 days for treated). Although sodium butyrate may not be effective enough 
to be considered a ’cure’ for SMA, it does demonstrate that inhibition of HDACs can 
ameliorate the severity of SMA symptoms and prolong the lifespan of SMA model mice. 
This initiated a large series of studies assessing the efficacy of HDAC inhibitors on the 
SMA phenotype, several of which have already progressed into clinical trials. Several of 
these, and their results, will be further discussed in this section. 
 
Valproic acid in SMA therapy 
 
 As the HDAC inhibitor sodium butyrate had been identified as an upregulator of 
smn2 mRNA and SMN protein levels, researchers hypothesized that other known HDAC 
inhibitors would have similar effects. Valproic acid (VPA) is a FDA approved drug and 
has been effectively utilized in the clinic for long-term treatment of epilepsy , and 
therefore would be an attractive therapeutic candidate for the treatment of SMA. In 2003, 





acid, increases the levels of full-length smn2 mRNA as well as SMN protein levels . 
In SMA patient fibroblast cell lines, Sumner et al. demonstrated an approximate 1.8-fold 
increase in the ratio of full-length to exon 7-deleted 
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SMN mRNAs, as well as an 
approximate 1.6-fold increase in SMN protein levels when treating with 10mM VPA for 
24 hours. Brichta, et al. demonstrated a 1.5-fold increase in the ratio of full-length to 
exon 7-deleted SMN transcripts, with an additional augmentation in total full length SMN 
mRNA via transcriptional upregulation, for a maximal increase of 5.2-fold in full-length 
SMN mRNA compared to untreated controls. In their system, Brichta, et al., also saw a 
1.8-4.2 fold increase in SMN protein levels, with activity varying significantly between 
different SMA patient fibroblast cell lines, indicating a significant amount of variation 
between the two systems. 
 As SMA is a motor neuron disease, the next step in determining the efficacy of a 
potential therapeutic is to test the effect of the compound on the tissue of interest: 
neurons. Brichta et al. tested the effect of VPA in rat organotypic hippocampal slice 
cultures (OHSC), as a model for VPA efficacy in neuronal tissues. When treated with 
2mM VPA for 12-48 hours, OHSCs demonstrated a 1.6 fold increase in rat smn mRNA, 
as well as a 1.8 fold increase in rat SMN protein levels. The authors hypothesized that 
since the splicing factors Htra2-β1 and SF2/ASF  have been shown to affect the splicing 
of smn transcripts, it could be the upregulation of these proteins which results in the 
alteration in smn splice isoforms seen upon treatment with VPA. Western blots indicated 
an approximate 1.4-fold and 3-fold increase in Htra2-β1 and SF2/ASF, respectively, 





Tsai and colleagues reported their investigations into the therapeutic effect of 
VPA in Type III SMA model mice in 2008 . SMA mice were treated from age 6 
months to 12 months with 0.2mg/ml VPA supplied in the drinking water, corresponding 
to 40-75mg/kg VPA consumed per day. VPA-treated mice showed some prevention of 
SMA-induced morphology changes, including lengthened tails, larger ears and larger 
gastrocnemius muscle (back of the calf). However, no other muscles showed an increase 
in size, nor was there a change in overall body mass. A greater degree of choline 
acetyltransferase (ChAT) staining, a motor neuron marker, in spinal cord slices of VPA-
treated versus untreated mice suggested that VPA treatment prevented some of the 
neuronal death seen in SMA, indicating that VPA may be a potential treatment for the 
amelioration of the effects of SMA. 
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 However, when Rak et al. investigated the effect of VPA on motor neurons 
isolated from SMA model mice in 2009, their findings were somewhat more negative . 
Although VPA treatment increased SMN levels in the motor neurons, it was 
concomitantly detrimental to several disease relevant parameters, such as axon outgrowth. 
VPA treatment decreased viability of the motor neurons after four days in culture and 
reduced the axonal outgrowth and growth cone size of the neurons. The authors 
determined that these effects were due to decreased excitability of the neurons upon VPA 
treatment, with the detrimental phenotype being similar to blockers of voltage gated 




 However, the positive effects of valproic acid treatment on motor function in a 




As VPA is an FDA-approved drug with well-understood dosing regimen, Phase I clinical 
testing (which is generally used to assess drug safety) could be bypassed. Instead, testing 
began with a small Phase II clinical trial which was performed to test the efficacy of VPA 
treatment on seven adult patients with the milder Type III and Type IV forms of SMA . 
As it was an open-label trial, all patients enrolled in the study were treated, and there 
were no untreated controls. Four of the six patients showed statistically significant 
(p=0.002) improvement in strength, measured via handheld dynamometry. 
Dynamometers are routinely used in kinesiology to quantify the force a specific muscle 
or group of muscles is capable of exerting. This method is considered a reliable method 
for determining alterations in strength over time in patients demonstrating neuromuscular 
weakness. Additionally, all six patients reported subjective improvements, such as 
improved ease of breathing and increased walking endurance. Based on this small study, 
VPA seemed to be beneficial for adult patients with milder forms of SMA. 
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 In 2009, a larger open label Phase II study of VPA was published by Swoboda et 
al. 218. This study enrolled a total of 42 patients: two Type I, 29 Type II and 11 Type III 
patients. All patients were 2 years old or older, to avoid the teratogenicity associated with 
VPA treatment. Dosages were in the range of 15-50mg/kg/day, similar to dosages utilized 
for anti-epileptic purposes . Carnitine levels were monitored, as the serum carnitine 
levels of the first 13 patients in the study decreased within the first three months of 
treatment. Two subjects demonstrated a decrease in motor function, which was reversed 
upon carnitine supplementation. Carnitine is utilized in cells for the transport of long 





catalysis and generation of ATP . Therefore, loss of carnitine upon VPA treatment 
resulted in decreased motor function likely due to “starved” muscle tissue. 
219,220
In this study, treatment with VPA was determined to be beneficial for non-
ambulatory Type II children, while older subjects showed no response or slight decrease 
in motility. This was due in a few subjects to a moderate amount of weight gain, which 
was gained as fat mass rather than lean mass, resulting in deterioration of motor function. 
The levels of SMN transcripts in blood samples were also monitored in the patients, as 
previous studies demonstrated increased levels of SMN transcripts in patient-derived cells 
. However, 213,214 SMN transcript levels in blood samples fluctuated greatly over the 
course of treatment, and overall seemed to decrease in the population. Previous reports 
utilizing testing VPA in patients and carriers indicated varying responses to the drug, 
therefore determination of biomarkers that can distinguish VPA-responders from non-
responders may assist in selection of the appropriate SMA population to test . 221
  
Phenylbutyrate in SMA therapy 
 
 Since several HDAC inhibitors had shown efficacy in increasing the levels of smn 
transcripts and proteins in patient cells, in 2004 Andreassi and colleagues tested the 
HDAC inhibitor 4-phenylbutyrate (PBA) .  Although the highly similar HDAC 
inhibitor sodium butyrate has also been tested in SMA 
222
211, PBA is more attractive as a 
therapeutic candidate, due to improved pharmacological properties, such as longer serum 
half-life . Fibroblasts derived from 16 SMA patients, ranging from Type I to Type III 





levels, with maximal responses ranging from approximately 1.2 to 4-fold increase. 
However, these increases dropped back to baseline within a few hours of treatment, 
unless PBA was re-administered to the cells every four hours. SMN protein levels were 
also quantified in three of these cell lines, and each showed a small, but not statistically 
significant increase in SMN protein levels, indicating that PBA may not be the most 
effective of the HDAC inhibitor tested to date. 
Brahe and colleagues performed a small, six patient and three carrier, clinical 
study assessing the efficacy of PBA at increasing the levels of SMN transcripts in 
leukocytes of SMA patients and carriers . Patients ranged in age from 2.5 to 38 years 
old, and were either Type II or Type III. All patients had three copies of SMN2. Carriers 
were recruited from the parents of the patients. Patients were treated for seven days with 
500mg/kg/day, divided evenly into 4 hour doses. Leukocytes were harvested from blood 
samples taken 1-3.5 hours after PBA administration. The levels of SMN transcripts 
changed between 0.4 to 2.4-fold in patients and 0.9 to 1.7 in carriers. Myometry was 
performed to determine whether muscle strength was altered, and found a statistically 
significant improvement across the population. However, again it was found that 
individual responses were greatly varied, with some patients showing no improvement. 
Altogether, this study indicated that PBA was safe for SMA patients and that it could 
increase the levels of SMN transcripts in peripheral blood leukocytes, in some cases. 
However, it did not show improved potency or efficacy compared to trial of another 
HDAC inhibitor valproic acid 
222
217.   
 





Another study conducted by Grzeschik and colleagues reported that hydroxyurea 
(HU), also an HDAC inhibitor, was a potential therapeutic agent for SMA 224. Their 
studies demonstrated that HU treatment of patient-derived lymphocytes was effective at 
increasing the ratio of full-length to exon 7-deleted SMN transcripts (FL:Δ7), as well 
SMN protein production. The ratio of FL:Δ7 SMN transcripts increased a maximal 2 to 3-
fold with 0.5mM HU treatment. Total levels of SMN mRNA did not change upon HU 
treatment, indicating the effect was due to alteration of splicing rather than activation of 
the promoter. SMN protein production however, showed maximal effect at 5µg/ml with 
protein levels decreasing below baseline at concentrations greater than 50µg/ml. The 
variability of response between the cell lines derived from patients was too great to 
determine statistical significance, although there was a trend with an average 1.3-fold 
increase across cell lines.  
However, these results spurred the testing of HU in SMA patients, and in 2008 
Liang and colleagues reported a small trial enrolling 33 SMA patients 225. The patients 
selected for study were the milder Type II and Type III individuals, and were treated with 
20-40mg/kg/day for 8 weeks. Although HU was demonstrated to be safe for SMA 
patients at these dosages, the effects were not statistically significant. However, there was 
a trend towards slight increases in muscle strength and elevation of blood SMN mRNA 
levels. The authors suggest that the lack of statistical significance may be due to the small 
sample size. Therefore, the authors initiated a larger, placebo-controlled clinical trial to 




efficacy of hydroxyurea in SMA patients 226, however this study also showed no 
improvement in the clinical markers of SMA. 
 
Second-generation HDAC inhibitors in SMA therapy  
 
HDAC inhibitors have been studied as anti-cancer agents, due to their ability to 
initiate growth arrest and apoptosis of neoplastic cells 227. Due to the intense interest of 
many academic laboratories as well as pharmaceutical companies in this area, second 
generation HDAC inhibitors have been developed, with improved potencies and 
efficacies against HDACs 228. Hahnen et al. investigated the efficacy of these second 
generation HDAC inhibitors in enhancing the levels of smn transcripts and SMN protein 
levels in human and rat organotypic hippocampal brain slices (OHSCs) and rat motor 
neuron-enriched cell fractions 229. The second generation HDAC inhibitors tested 
included the hydroxamic acids as well as the benzamides. The hydroxamic acids were: 
suberoylanilide hydroxamic acid (SAHA, Vorinostat), m-carboxycinnimic acid bis-
hydroamide (CBHA) and suberoyl bishydroxamic acid (SBHA) 228. The bezamides were: 
N-(2-Aminophenyl)-4-[N-(pyridine-3-ylmethoxycarbonyl)aminomethyl]benzamide (MS-
275) and 4-Dimethylamino-N-(6-hydroxycarbamoylhexyl)benzamide N-Hydroxy-7-(4-
dimethylaminobenzoyl) amino-heptanamide (M344) 230,231. The authors selected these 
tissues for testing in order to determine whether these compounds were active in a CNS-
derived cellular context. The compounds SAHA, SBHA, CBHA and M344 and the 
positive control VPA increased SMN protein levels in F98 rat glioma cells approximately 




low micromolar concentrations, while SBHA and CBHA were active in the 50-250µM 
range. VPA was used at 2mM. SAHA, M344 and VPA also increased wild-type murine 
smn transcript levels approximately 1.8 to 2.5 fold, at their respective relevant 
concentrations. Additionally, higher concentrations of SAHA (32-64µM) demonstrated 
approximately 1.8-fold increase in SMN protein levels in human OHSCs after 48 hours 
of treatment, demonstrating SAHA’s efficacy in human CNS tissues. 
Due to the success of SAHA’s efficacy in the tissue explants, Riessland and 
colleagues tested the compound’s effects on two severe mouse models of SMA 232. 
Treatment of pregnant heterozygote mothers with 200mg/kg/day of SAHA, a dosage 
which has been demonstrated to decrease histone acetylation levels in the brain 233, 
indicating that an effective concentration is passing the blood-brain barrier. SAHA 
treatment rescued the embryonic lethality evident in the homozygous pups, as the treated 
mothers birthed five SMA pups, while the solvent-treated mothers only birthed one. 
However, all homozygote pups developed an SMA-like phenotype, indicating that SAHA 
is not able to prevent the onset of disease. 
 To determine if SAHA could ameliorate the symptoms of disease, it was further 
tested in the newborn SMA pups. However, the high dosage of SAHA utilized in the 
adult mothers demonstrated significant toxicity in the SMA pups, and the dosage had to 
be reduced to 25mg/kg/day. At this dosage, mouse survival was increased 30% (P<0.001), 
extending survival from 9.9 to 12.9 days, demonstrating a significant improvement in the 
SMA phenotype. SAHA-treated animals also demonstrated improved motor performance 




treatment of SMA. As SAHA is an FDA-approved drug, clinical trials may soon be 
forthcoming. 
  
Indoprofen in SMA therapy 
 
HDAC inhibition is not the only mechanism by which small molecule can 
upregulate SMN protein levels. Indoprofen, an analog of ibuprofen, was discovered as a 
modulator of SMN protein levels in 2004 by Lunn and colleagues 234. Indoprofen was 
discovered in a small molecule screen of approximately 47,000 compounds using a SMN 
minigene-luciferase reporter system 235. In this system, exons 6-8 and intervening introns 
of either the SMN1 or SMN2 gene are fused with the luciferase gene. The luciferase gene, 
however, is in frame only when exon 7 is spliced properly. Therefore, this cell line can be 
used to identify small molecules that increase the inclusion of exon 7 in the SMN2 
background by assaying for increased luciferase expression. The SMN1-luciferase 
construct served as a control for small molecules that may cause increases in luciferase 
signal non-specifically, e.g. through global enhancement of translation. Indoprofen was 
identified as a compound that significantly increased SMN2-luciferase signal relative to 
SMN1-luciferase. Indoprofen is a non-steroidal anti-inflammatory drug (NSAID). 
NSAIDs act as analgesics by inhibiting the cyclooxygenases COX-1 and COX-2, which 
are important in the inflammatory pathway, as well as potentially regulating other pain-
regulation pathways 236. Inhibition of COX-1 can lead to irritation of the gastrointestinal 
tract 237. Although indoprofen was initially FDA-approved, it was pulled from shelves in 




Through a structure-activity relationship study testing other NSAIDs, including the 
closely related analog ibuprofen, indoprofen was determined to be the only NSAID tested 
with activity in the luciferase assay, suggesting the mechanism of action was not through 
inhibition of the COX enzymes. Human SMA patient Type I fibroblast cells treated with 
~10µM indoprofen showed a reproducible average 1.13-fold increase in SMN protein 
levels, which was moderate but statistically significant (p < 0.014). Indoprofen’s effect 
on a severe mouse model of SMA was tested in the Smn-/-, TgSMN2+/- model, in which 
the murine smn gene is replaced by the human smn2 transgene 56. The homozygous 
embryos from this mouse model die on average at embryonic day 11. Heterozygous mice 
were crossed and the pregnant mothers were treated with IP injections of 5mg/kg 
indoprofen twice daily for the initial 14 days of pregnancy, resulting in an average 3.0µM 
indoprofen concentration in the embryos of the treated mothers by embryonic day 13. At 
day 14, the embryos were genotyped to determine the number of surviving homozygotes. 
In the untreated mothers (n=7), none of the litters contained any Smn-/-, TgSMN2+/- 
embryos, however three of the seven indoprofen-treated mothers retained Smn-/-, 
TgSMN2+/- embryos. Although this result was not statistically significant due to the small 
sample size (p = 0.096), the increases in litter size and number of SMA embryos 
suggested a trend of increased viability upon indoprofen treatment.  
Due to the potential therapeutic effect of indoprofen, the Spinal Muscular Atrophy 
Project selected this structure for additional medicinal chemistry efforts 
(http://www.smaproject.org/). The SMA Project was established by the National Institute 
of Neurological Disorders and Stroke (NINDS) to focus on pre-clinical drug development 




clinical trials. Medicinal chemistry efforts by the SMA Project, reported at the 2007 SMA 
Summit on Drug Development 238, were shown to be successful in creating analogs of 
indoprofen that retain SMN upregulation but do not inhibit COX-1, thereby removing the 
risk of negative gastrointestinal effects. Additionally, the indoprofen analogs generated 
have greatly improved blood-brain barrier penetration, a necessary property for a CNS-
active drug. Mouse trials will hopefully be forthcoming for these promising analogs. 
 
Looking towards the future for SMA therapeutics 
 
Although a great degree of progress has been made toward identifying small 
molecule therapeutics for Spinal Muscular Atrophy, the limited efficacies of the 
compounds tested in clinical trials to date demonstrate how much further we need to go 
in order to develop a cure for this fatal disease. Interest in alternative therapeutics such as 
gene therapy and cell replacement have burgeoned in the SMA field, and several attempts 
have been made to rescue the SMA phenotype in mouse models of SMA utilizing viral 
vectors. The first study utilized intramuscular injections of a self-inactivating lentiviral 
vector expressing SMN into young SMA pups 23, which increased survival of the SMA 
mice 20-38% (3 and 5 days, respectively). While these results appear somewhat milder 
than expected, it has been argued that this type of viral injection may not be an efficient 
method of transducing neurons 239.  
Another method, utilizing high-titer systemic injections of the self-
complementary (sc) AAV serotype 9 vector (scAAV9) have demonstrated transduction of 




transduce a SMN expression vector into the motor neurons of postnatal (PN) day 2 and 
day 10 SMA model mice 241. Transgene expression of SMN starting at PN2 significantly 
improved motor function and demonstrated strong rescue of survival, as scAAV9-GFP all 
died before PN25 but all scAAV9-SMN transduced mice lived past PN60. However, 
another study by Valori and colleagues using similar methodology reported a lower 
degree of rescue. In their study, approximately 80% of the injected mice demonstrated 
increased survival, extending life span from 11.2 days in the scAAV9-GFP injected mice 
to 69.1 days in the scAAV9-SMN injected mice 242. 
An unfortunate discovery from a therapeutics perspective was that transduction of 
PN10 mice in the Foust study showed no demonstrable rescue of the motor function or 
survival 241. This suggests that there may be a finite window of opportunity for viral-
mediated rescue of the SMA phenotype. 
Although advances in gene therapy are ongoing, it is unclear how long they will 
take to get into the clinic, and therefore there is still a need for identification of new, 
effective small molecule therapeutics. Additionally, novel small molecules which 
modulate SMN protein levels are needed in order to probe the cellular mechanisms 
involved in SMN regulation. Identifying new cellular pathways capable of altering SMN 
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Chapter 2. Small molecule upregulator reveals regulation of SMN protein levels by 
Ras 
 
High-throughput screen for small molecule upregulators of SMN protein levels 
 
Bioactive small molecules have enabled major advances in biological research 
and drug development. Although many efforts have focused on the identification of small 
molecule inhibitors of protein function, the ability to upregulate protein abundance or 
otherwise increase protein activity can provide complementary insights that cannot be 
obtained through loss of function studies alone 1. Although the number of compounds 
known to function as protein upregulators is quite small, they have important research 
and therapeutic applications. Examples include histone deacetylase inhibitors, used in the 
treatment of psychiatric conditions, neurologic disorders and cutaneous T cell lymphoma 
2-4, and proteasome inhibitors, used in the treatment of multiple myeloma 5 and for the 
study of the ubiquitin-proteasome system 6.  
Unfortunately, these known upregulating compounds lack specificity, altering the 
levels of hundreds to thousands of gene products 7. Such broad spectrum effects, in 
addition to potentially being therapeutically undesirable, make these compounds 
unsuitable for investigations of mechanisms regulating the abundance of an individual or 
limited number of proteins. Small molecules that can upregulate specific protein targets 
are needed in order to expand the small molecule toolkit, and would be especially 
advantageous for the study of loss of function diseases. However, we lack systematic 




In order to address this need, we developed a high-throughput screening approach 
to identify small molecule upregulators of a specific protein. This assay detects increases 
in the abundance of a target protein after treatment with small molecule libraries. We 
selected the Survival of Motor Neuron (SMN) protein as a target for modulation. 
Decreased SMN protein levels result in the loss of function neurodegenerative disease 
Spinal Muscular Atrophy 8. In patients, SMN protein levels are severely decreased to 
10% of carrier levels, due to homozygous deletion of the survival of motor neuron 1 
(smn1) gene, but retention of the smn2 gene 9. The smn2 gene is nearly identical to smn1, 
but contains a translationally silent C to T transition which causes the smn2 pre-mRNA to 
be aberrantly spliced, generating only ~10% of the full-length, functional protein 
produced by the smn1 gene 10. This small amount of SMN protein prevents the 
embryonic lethality seen in an SMN null background 11, but cannot prevent the motor 
neuron degeneration observed in SMA. Small molecule upregulators of SMN could 
provide novel insights into the regulation of SMN protein levels, leading the way to new 
therapeutic targets. 
We screened 69,189 small molecules and discovered three SMN-upregulating 
compounds. Mechanistic investigations of the most effective compound, Chemical 
Upregulator of SMN Protein-1 (cuspin-1), revealed that increasing Ras signaling 








Screen development and optimization 
 
In order to identify compounds upregulating SMN protein levels, we developed a 
high-throughput screen for monitoring the levels of endogenous SMN protein in SMA 
patient fibroblast cells. Previous screens searching for SMN-upregulating compounds 
focused on altering either the transcription or splicing of smn2 12,13. Our screen focuses 
on the desired final product, SMN protein abundance, in order to be inclusive of all 
aspects of SMN protein regulation, from transcription through degradation. This method 
permits identification of small molecule upregulators of SMN protein without bias 
towards their mechanism of action. 
To quantify SMN protein levels in a 384-well format, the cytoblot assay 14, a 
modified enzyme-linked immunosorbent assay (ELISA), was optimized for microtiter-
based screening using SMA patient fibroblasts. A schematic of the primary screening 
workflow is shown in Figure 1. The assay protocol involved the seeding of cells and 
subsequent treatment with small molecules for 48 hours. This incubation period was 
selected to allow sufficient time for the compounds to increase SMN protein levels, while 
limiting the depletion of nutrients and accumulation of toxins in the microtiter format 
during prolonged incubation 15.  After incubation, cells were fixed, permeabilized and 
incubated with primary and secondary antibodies in-plate. Horseradish peroxidase-
derived chemiluminescence was detected using an automated platereader. The optimized 
SMN cytoblot is a suitably robust format for detecting SMN levels in cells, as indicated 
by a Z’ factor 16 of 0.5 in the optimized assay, using the #3814 SMA carrier cell line as a 





Figure 1. Schematic of the primary screening workflow. SMA patient fibroblast cells 
are seeded into 384-well plates and incubated for 48 h with a single compound per well. 
After 48 h, cells are fixed, permeabilized and SMN protein levels are quantified by 
incubation with a primary anti-SMN antibody, and a secondary antibody conjugated to 
horseradish peroxidase (HRP). Incubation of HRP with a luminal solution produces 
photons in correlation with the amount of bound HRP; the amount of light produced per 




Screening and hit validation 
 
Compounds screened in this assay were from two libraries assembled from 
commercial vendors. The first was our previously reported small molecule library 17, 
described in Materials and Methods. The second library was composed of compounds 
specifically chosen for their predicted ability to cross the blood-brain barrier (BBB), an 
important first step in small molecule selection, as the development of CNS-active 
compounds is impeded by the inability of a large portion of compounds to penetrate the 
BBB. Small molecules for the second library were selected by in silico filtering for 
compounds likely to be BBB-penetrant and filtering out known toxic and reactive 
species. This work was performed by Dr. Andras Bauer, a Stockwell Lab member. The 
resultant set of compounds was dubbed the “BBB library”.   
Primary screening was performed in triplicate in 9677 SMA patient fibroblast 
cells in 384-well format. A total of 69,189 small molecules were evaluated in the SMN 
cytoblot assay. To remain inclusive of compounds with moderate efficacy, a ‘hit’ was 
defined as having a median signal greater than two standard deviation from the median of 
the untreated wells. The 1,106 compounds passing hit criteria in the primary screen were 
retested in dose-response series in three SMA patient fibroblast lines (232, 3813 and 
9677). The 105 candidates showing dose-response activity in at least two cell lines were 
tested by Western blot. Three structurally distinct compounds were found to significantly 






Figure 2. Dose-response of the SMN-upregulating compounds 72 and 81.  
9677 SMA patient fibroblast cells were incubated with (A) compound 72, or (B) 
compound 81 for 48 h prior to SMN protein quantification in plate-based assay. The data 
represent the average of triplicates ± SEM. RLU: relative luminescence units. Small 
molecule structures and Western blot quantification of SMN-upregulating activity are 
shown to the right of each dose-curve. Values below Western blots represent 






Figure 3. Cuspin-1 upregulates SMN protein levels in SMA patient fibroblast cells. 
(A) Structure and molecule weight of the optimal hit compound identified in our screen, 
Chemical Upregulator of SMN-1 (cuspin-1). (B) Dose-response curve of 9677 SMA 
patient fibroblast cells treated with cuspin-1 for 48 h. The data represent the average of 
triplicates ± SEM. RLU: relative luminescence units. P-values were calculated using two-
tailed t-test. (* = p<0.01, ** = p<0.001) (C) Western blot and graph quantification of 
9677 cells treated with a dose-curve of cuspin-1 for 48 h. SMN protein levels are 





scaffolds were in the range of 10-20 µM, typical for hits from high-throughput, cell-based 
screens. A summary of the screen can be found in Table 1. 
We focused on the most robust of these three hits, a bromobenzophenone analog 
we designated cuspin-1 (Chemical Upregulator of SMN Protein-1, Figure 1B). Cuspin-1 
showed strong activity in the plate-based dose response assay (Figure 3B) and 
increasedSMN levels by 50% compared to DMSO-treated controls at 5 µg/mL (18 µM) 
in SMA patient fibroblast cells (Figure 3C). Toxicity was observed at concentrations at or 
above 80 µg/mL (720 µM), providing a robust effective concentration (EC) to lethal 
concentration (LC) ratio for cell culture studies. It has proven challenging to find small 
molecules that significantly upregulate endogenous SMN protein levels 18. Thus, cuspin-1, 
despite its modest overall effect, was selected as a suitable probe for further 
characterization as it showed moderate activity and low cellular toxicity. 
The ability of cuspin-1 to upregulate SMN protein levels in diverse genetic 
backgrounds was tested in a panel of cell lines, including wild-type and SMA human and 
rodent cells (Table 2). Although cuspin-1 was active in the majority of human cell lines, 
it was inactive in the rodent lines tested, suggesting that its target or mechanism may not 
be conserved across species.  
 
Structure-activity relationship of cuspin-1 
 
To evaluate the features necessary for the activity of cuspin-1, a structure-activity 
relationship (SAR) analysis was undertaken through analog synthesis and testing. 





Table 1. Summary of small molecule screen. Listed are number of compounds in each 
library screened. Additionally listed are the number of small molecules which passed 
primary hit critera (‘Hitpicked’), passing secondary hit criteria (‘Tested by WB’), and 
confirmed in tertiary assay by quantification of SMN protein levels by Western blot. 
 
 
Table 2. Genotype-specificity testing of cuspin-1. Table lists designations and origins 
of each cell line, as well as the mean percent increase of SMN normalized to actin upon 





similar analog (5-bromo-3-pyridinyl)(4-ethylphenyl)-methanone, designated cuspin-2, 
increased SMN protein abundance to comparable levels as cuspin-1. Although cuspin-2  
was active, it did not improve upon the potency or efficacy of cuspin-1. All other cuspin-
1 analogs that we synthesized, using the synthetic scheme in Figure 4B, including 
analogs lacking either the bromine, nitrogen or methyl group, were inactive (Figure 4C). 
Additionally, while cuspin-2 demonstrated that extension of the methyl to an ethyl group 
retained activity, extension to a propyl group rendered the compound inactive, indicating 
a possible steric clash with cuspin-1’s target. As modifications to the cuspin-1 scaffold 
generally resulted in loss of activity, further work is required to identify modifications 
that would improve the potency and efficacy of the compound. However, the current 
cuspin-1 scaffold represents a valuable tool for the study of SMN regulation. 
 
Cuspin-1 reveals link between Ras signaling and SMN protein levels 
 
In exploring the mechanism of action of cuspin-1 we observed that treatment with 
cuspin-1 increased phosphorylation of extracellular signal-related kinase (Erk) (Figure 
5A). Proteins involved in other signaling pathways, such as Akt, were not activated 
(Figure 5A). The canonical pathway resulting in phosphorylation of Erk (p-Erk) is the 
Ras-Raf-MEK signaling cascade 19. To test whether Ras could be responsible for the 
cuspin-1 mediated upregulation of SMN protein, Ras signaling was increased in #3813 
SMA patient fibroblast cells by expression of a constitutively active form of Ras 






Figure 4. Structure-activity relationship of cuspin-1. 
(A) Structures and activities of the highest similarity commercially-sourced cuspin-1 
analogs. (B) Friedel-Crafts acylation scheme for analogs synthesized in-house. (C) 





compared to vector alone (Figure 5B). The 5-fold increase in p-Erk in the NRasG12D 
expressing cells confirmed a strong increase in Ras signaling in these cells. Similar 
increases in SMN and p-Erk levels were observed in #9677 and #232 SMA patient 
fibroblasts, indicating this effect of NRasG12D is not unique to one SMA patient cell line.  
Further experiments investigating the effect of activated Ras on SMN protein 
levels, could not be performed in the SMA patient cell lines, as non-transformed cells 
senesce shortly after introduction of oncogenic Ras 20 Therefore, we utilized the 
tumorigenic HRasV12-expressing BJeLR cell line for subsequent experiments. The G12V 
mutation in the HRasV12 protein is functionally equivalent to the G12D mutation used 
previously, as they both inactivate GTPase activity, rendering the proteins constitutively 
active. BJeLR cells are an engineered cell line created by sequential introduction of viral 
and mammalian genetic elements into parental BJeH human foreskin fibroblasts 20. The 
BJeHLT cell line contains all genetic elements found in the BJeLR cell line, with the 
exception of HRasV12. Comparison of SMN protein levels in the BJ cell lines 
demonstrated a 3-fold increase in SMN protein in the BJeLR cell line compared to the 
parental cell line, BJeH (Figure 5C). The lack of increase in SMN in the BJeHLT cell line 
indicates that activated Ras is the sole genetic element responsible for upregulation of 
SMN protein abundance in this cell line (Figure 5C). Interestingly, a literature review 
revealed that this phenotype had been noted before, in a comparison of the SMN protein 
levels in the oncogenic cell line HeLa compared to normal fibroblasts 9, however the 
authors did not discuss or follow up on this observation. 
This upregulation in SMN protein could be the result of either global upregulation 





Figure 5. Increased Ras signaling upregulates SMN protein abundance. 
(A) Western blot analysis of 9677 cells treated with 10µg/ml cuspin-1, harvested at 
indicated time points and blotted for p-Erk, total Erk, p-Akt, total Akt and tubulin. Graph 
shows quantification of phospho-protein to respective total protein ratios, normalized to 




the observed effect on SMN protein levels was due to global upregulation of translation, 
the levels of several control proteins were examined by Western blot. These proteins are 
in 3813 SMA patient fibroblast cells transduced with either vector alone or constitutively 
active NRasG12D viral plasmid. Graph shows fold increase of SMN compared to vector-
only control, normalized to tubulin as loading control. (C) Comparison of the engineered 
tumor cell line BJeLR (eLR), expressing HRasV12, versus the parental line (eH) and the 
isogenic line BJeHLT (eHLT) which contains all genes ectopically expressed in BJeLR 
with the exception of HRasV12. Samples were blotted for SMN and several control 
proteins. Graph shows the fold increase of SMN in BJeHLT and BJeLR compared to 
BJeH, normalized to actin as loading control. In (A) and (C) the data represents the 





involved in diverse cellular processes, including glucose metabolism (GAPDH), the 
cytoskeleton (actin), translation (eIF4E), and cell death (Smac). The abundance of these  
proteins remained unaltered by oncogenic Ras expression (Figure 5C), suggesting a level 
of specificity to Ras-mediated SMN upregulation. We have shown that multiple isoforms 
of Ras can upregulate SMN protein levels in diverse cell lines. 
 
Mechanistic studies of Ras-mediated upregulation of SMN protein levels 
 
To investigate the mechanism underlying SMN protein upregulation by activated 
Ras, we utilized the BJ cell lines to determine the cellular process through which Ras 
exerts its effect on SMN protein levels. First, we tested whether alterations in 
transcription or splicing of smn mRNA were responsible for the increase in SMN protein 
abundance. The BJeLR (+HRasV12) cell line did not show increased levels of either full-
length or Δ7 smn mRNA, nor did it have an altered ratio of the spliced isoforms, as 
compared to the parental line BJeH (-HRasV12) (Figure 6A). This lack of increase in smn 
mRNA levels suggests that the upregulation of SMN protein levels was not due to 
activation of p38 mitogen-activated kinase, a Ras effector protein, which was recently 
shown to upregulate SMN protein levels via stabilization of smn mRNA 21. Unexpectedly, 
the BJeLR line showed consistently lower levels of smn mRNAs than the BJeH parental 
line. This could be due to a feedback mechanism downregulating smn transcripts in 
response to strongly elevated SMN protein levels. 
Next, we examined the effect of increased Ras signaling on SMN turnover. 





Figure 6. Increased Ras signaling enhances SMN translation rate 
(A) Quantification of RT-PCR of full-length (smnFL) and exon 7-deleted (smnΔ7) smn 
mRNA levels from BJeH (-HRasV12) and BJeLR (+HRasV12) cells. Transcript cycle times 
were normalized to hprt to control for total mRNA. Data represents the average of three 
independent samples ± standard deviation. (B) Representative Western blot analysis of 
SMN and actin in BJeH (-HRasV12) and BJeLR (+HRasV12) cells treated with the protein 
synthesis inhibitor cycloheximide (CHX [10µM]) for indicated times. Quantification of 
SMN to actin ratio normalized to respective untreated control (0h) is shown below each 
lane. (C) Phosphorimager bands and quantification of translation rate analysis of SMN 
and actin in BJeH (-HRasV12) versus BJeLR (+HRasV12) cells. Data represent mean ± 
standard deviation, n=2. P-values were calculated using two-tailed t-test. (* = p<0.01) 
(D) Phosphorimager lanes demonstrating equivalent levels metabolic labeling in BJeH (-




nascent SMN peptides in order to quantify the half-life of SMN. The half-life of SMN in 
the BJ cell lines was ~3 hours, similar to previous reports 22,23. The degradation rate of 
SMN protein remained unchanged in the HRasV12-expressing cells, indicating that 
increased Ras signaling does not affect the rate of SMN degradation (Figure 6B). 
Having ruled out alterations in transcription, splicing and turnover, we tested 
whether HRasV12 affected the translation rate of SMN. A translation rate assay, using 
radioactive 35S-methionine and cysteine to label newly synthesized protein with 
subsequent immunoprecipitation of proteins of interest, was performed to quantify the 
translation rate of SMN. HRasV12-expressing cells showed a significant 2.5-fold increase 
(p<0.01) in the rate of SMN translation compared to parental cells (Figure 6C). No 
differences were observed in the total amount of label incorporated in each cell line 
(Figure 6D), suggesting the increased translation rate of SMN protein is unlikely to be 
due to a global increase in translation. We have determined that activated Ras signaling 
upregulates SMN protein abundance via translational regulation, however further 
investigation will be required to determine the exact nature of the connection between 
Ras signaling and SMN translation rate. 
We developed a high-throughput screen for identification of small molecule 
upregulators of the SMN protein and identified three novel SMN-upregulating 
compounds. Mechanistic studies of cuspin-1 led to the discovery that Ras signaling 
regulates SMN protein abundance at the level of translational regulation. In addition to 
the novel SMN regulatory pathway identified, this study provides a proof of principle that 
mechanistically unbiased screens can uncover unexpected connections between cellular 




The Raf-MEK-Erk pathway is not responsible for Ras-mediated upregulation of SMN 
 
Although the connection between Ras signaling and SMN protein level increase 
was discovered due to an observed increase in p-Erk staining upon cuspin-1 treatment, 
further experiments indicated that while Ras activation is necessary for SMN 
upregulation, activation of the Raf-MEK-Erk pathway is not. The importance of the Raf-
MEK-Erk pathway was tested by transducing 3813 SMA patient fibroblast cells with 
retroviral plasmids expressing the constitutive active proteins NRasG12D, BRafV600E or 
MEKS218D,S222D (from hereon referred to as NRasG12D, Raf and MEK). Although Raf and 
MEK both increased p-Erk levels, to a higher degree even than NRasG12D, they did not 
increase SMN protein levels (Figure 7A). Only NRasG12D expression was able to 
upregulate SMN protein levels. This data suggested that the Raf-MEK-Erk pathway is 
not the effector pathway of Ras responsible for mediating SMN upregulation.  
To confirm that the Raf-MEK-Erk pathway was not involved in upregulation of 
SMN protein levels, the MEK inhibitor U0126 24 was tested to determine if it could 
inhibit the upregulation of SMN protein levels observed upon treatment with cuspin-1. 
Since MEK is the kinase responsible for phosphorylation of Erk, U0126 activity in these 
cells was demonstrated by blotting for p-Erk levels, which were decreased to 
approximately 5% of untreated cells. Interestingly, treatment with cuspin-1 increased 
phosphorylation of Erk 2-fold, regardless of the whether the cells were also treated with 
U0126 (Figure 7B). Additionally, U0126 co-treatment did not reduce the upregulation of 
SMN protein levels due to cuspin-1 treatment. However, U0126 treatment did decrease 





Figure 7. SMN upregulation due to increased Ras signaling is not mediated 
by the Raf-MEK-Erk effector pathway. (A) Western blot analysis of SMN protein 
levels in 3813 SMA patient fibroblast cells transduced with either empty viral vector 




transduction. Increased phosphorylation of Erk is observed upon expression of any of the 
three oncogenic proteins, indicating activation of the Erk-mediated signaling pathway, 
however only expression of NRasG12D upregulates SMN protein levels. Graph shows fold 
increase of SMN and phosphorylated Erk (p-Erk) compared to vector-only control, 
normalized to tubulin as loading control. (B) Western blot analysis of SMN, tubulin and 
p-Erk in 9677 SMA patient fibroblast cells treated with 5µg/mL or 10µg/mL with or 
without 10µM of the MEK inhibitor U0126 for 48 h. Graph shows fold increase of SMN 
compared to DMSO-treated control, normalized to tubulin as loading control. Data 
represent mean ± standard deviation, n=2.Inhibition of MEK is evident from the 95% 
decrease in basal p-Erk levels, however cuspin-1 treatment results in ~140% increase in 




toxicity inherent to U0126 treatment. Together with the lack of SMN-upregulating 
activity of Raf and MEK overexpression, these results strongly suggest that the Raf-
MEK-Erk pathway is not involved in Ras-mediated increase of SMN protein levels. 
A wider range of small molecule inhibitors of Ras effector kinases were also 
tested in the HRasV12-expressing BJeLR cell lines, to determine whether inhibition of any 
of these downstream pathways of Ras could reduce the upregulated SMN levels observed 
in these oncogenic Ras-expressing cells. BJeLR cells were treated for 24 hours with 
either 5µM or 10µM U0126 (MEK inhibitor), 7µM SP600125 (Jnk inhibitor), 1µM 
Wortmannin (PI3K inihibitor-1), 25µM LY294002 (PI3K inhibitor-2), 2µM Akt 1 and 2 
inhibitor (Akt inhibitor), 5mM 3-methyladenine (PI3K inhibitor-3) and 1µM Raf-1 
inhibitor. These concentrations were previously determined by Dr. Adam Wolpaw, 
another member of the Stockwell Laboratory, as maximizing efficacy while limiting 
toxicity in the BJeLR cell line (personal communication). None of these treatments 
demonstrated an effect on SMN protein levels, indicating that these pathways are likely 
not involved in Ras-mediated upregulation of SMN protein levels (Figure 8). However, 
overexpression studies are still required in order to conclusively eliminate these pathways 
as modulators of SMN protein levels.  
Although surprising, the discovery that the Raf-MEK-Erk pathway does not 
mediate activated Ras-induced upregulation of SMN protein levels does not invalidate 
the results observed upon cuspin-1 treatment. The elevation of phosphoryated Erk in 





Figure 8. Small molecule inhibition of downstream Ras effector kinases does not 
inhibit oncogenic Ras-mediated upregulation of SMN protein levels. Western blot 
analysis of SMN and tubulin levels in BJeLR fibroblast cells expressing an oncogenic 
isoform of HRas (HRasV12) treated with various kinase inhibitors for 24 h. Graph 
quantification of SMN normalized to tubulin as loading control compared to DMSO-





directly responsible for the upregulation of SMN, it still serves as a biomarker for Ras 
activation. Preliminary investigations aimed at determining the downstream Ras effector 
pathways regulating SMN protein levels have been negative to date, therefore further 
work is required to identify the relevant effector pathway. Due to the extensive number of 
targets downstream of Ras activation, it is possible that a pathway we have yet to explore 
will prove to be the one responsible for the Ras-mediated upregulation of SMN protein 
levels. 
 
Mammalian target of rapamycin modulates SMN protein levels 
 
As the Ras-mediated upregulation of SMN protein was determined to be at the 
level of translational regulation, it was investigated whether this effect could be mediated 
via the translational regulator mammalian target of rapamycin (mTOR) 25. Several 
important cellular signaling pathways converge on mTOR, including those responsible 
for sensing the intracellular levels of amino acids and growth factors 26. Sufficient levels 
of both of these factors result in activation of mTOR signaling, resulting in pro-growth 
downstream effects. Activated mTOR inhibits the translational repressor eukaryotic 
initiation factor 4E-binding protein (4E-BP1), via hyperphosphorylation . Additionally, 
activated mTOR phosphorylates ribosomal protein S6 kinase 1 (S6K1), resulting in 
enhanced translation . Inactivation of mTOR signaling, via starvation or treatment 
with the potent small molecule inhibitor rapamycin , conversely downregulates protein 




30,31, demonstrating its crucial role in nutrient-mediated 





The starvation response downregulates SMN protein levels 
 
The mammalian target of rapamycin (mTOR) protein is a key regulator of the 
starvation response, integrating signals from several homeostatic pathways, including 
amino acid and growth factor sensing pathways. As the signaling output from mTOR is 
pro-growth, lack of stimulatory input, such as starvation, inhibits mTOR signaling. To 
determine whether inhibition of mTOR signaling could modulate SMN protein levels, 
SMA patient fibroblasts were placed under starvation conditions by incubation in Earle’s 
Balanced Salt Solution (EBSS). EBSS contains the inorganic salts potassium chloride, 
sodium bicarbonate, sodium chloride and sodium phosphate monobasic as well as D-
glucose, but no amino acids or serum components. Starvation of SMA patient fibroblasts 
in EBSS for 24 hours decreased SMN protein 50-60%, indicating that SMN protein levels 
were responsive to starvation conditions (Figure 9, first four lanes). 
 
SMN downregulation is stimulated by serum deprivation 
 
To determine whether introduction of amino acids or serum could rescue the 
decrease in SMN, either amino acids or dialyzed serum were added to the EBSS. The 
FBS was dialyzed in PBS overnight in dialysis membrane with a 6-8,000 molecular 
weight cutoff (Spectra/Por 132 655) in order to remove amino acids naturally found in 
serum. Adding amino acids to the EBSS did not rescue the starvation-induced decrease in 






Figure 9. Serum starvation downregulates SMN protein levels.  
9677 SMA patient fibroblast cells were cultured either in normal 15% serum cell culture 
media, or starved of both serum and amino acids in Earle’s Balanced Salt Solution 
(EBSS). Western blot analysis of SMN and tubulin demonstrate a ~70% decrease in 
SMN protein levels, normalized to tubulin as loading control, upon starvation in EBSS 
for 24 h. Data represents the mean ± standard deviation, n=2.The addition of serum 
(dialyzed to remove amino acids) rescues starvation-mediated downregulation of SMN 





protein levels up to 80% of the unstarved control (Figure 9). It is unclear why addition of 
serum did not completely rescue. However as serum factors smaller than 8kDa would 
have been dialyzed out along with the amino acids, it is possible that one or more of these 
smaller factors are important for mediating this effect. Examples of serum factors under 
8kDa include hormones or small growth factors, such as insulin-like growth factor 1, 
which has a molecular weight of 7.6kDa 32.  Although the rescue was not complete, these 
results indicate that lack of serum factors, but not amino acids, can significantly decrease 
SMN protein levels.  
Of interest, serum starvation had no effect on SMN levels in the BJeLR cell line, 
which overexpresses HRasV12, or the oncogenic HT1080 cells. This suggests that 
increased Ras signaling can functionally interact with mTOR in such as way as to prevent 
the downregulation of SMN protein levels due to starvation-mediated inhibition of 
mTOR signaling.  
 
Inhibition of mTOR by the small molecule rapamycin reduces SMN protein levels 
 
As mTOR signaling is generally considered to be dependent on both amino acid 
and serum signaling pathways, to conclusively determine whether inhibition of mTOR 
signaling was responsible for the decrease in SMN protein levels SMA patient fibroblast 
cells were treated with rapamycin, a potent small molecule inhibitor of mTOR signaling 
29.  
To determine the optimal concentration of rapamycin, SMA patient fibroblast 





Figure 10. Treatment with the mTOR inhibitor rapamycin decreases SMN protein 
levels. (A) Western blot analysis of SMN and tubulin in 9677 SMA patient fibroblast 
cells treated with 1nM, 10nM, 0.1µM or 1 µM of the mTOR inhibitor rapamycin for 24 h. 




control. Rapamycin demonstrated high potency, showing maximal efficacy of SMN 
decrease (40% decrease) at 1nM. (B) Time course of rapamycin treatment (5nM) in 9677 
SMA patient fibroblast cells, or (C) BJeH wild-type human fibroblast cells. Graphs 
quantify SMN levels normalized to tubulin, compared to DMSO-treated controls. For (B) 




concentrations resulted in a ~40% decrease in SMN protein levels (Figure 10A), 
indicating rapamycin’s activity on SMN protein levels was maximal at low nanomolar  
concentrations. I selected 5nM as the optimal rapamycin concentration for inhibition of 
mTOR signaling for future studies. To determine the time course of SMN protein 
reduction, cells were treated with 5nM rapamycin in a time course lasting 48 hours. 
Rapamycin treatment resulted in a ~30% reduction in SMN protein levels within 20 
hours, which remained consistent through the 48 hour time point (Figure 10B). After 48 
hours treatment with rapamycin, cells were significantly reduced in viability. BJeH, a 
wild-type fibroblast cell line, showed a similar response to the SMA fibroblast cell line 
(Figure 10C), indicating this effect of rapamycin is independent of basal SMN protein 
levels.  
Interestingly, just as serum starvation of BJeLR cells showed no demonstrable 
effect on SMN protein levels, the same held true for rapamycin treatment. BJeLR cells 
were treated with 5nM or 50nM rapamycin for 24 hours, however this did not result in 
decreased SMN protein levels (Figure 11). Rapamycin’s inhibition of mTOR signaling 
was confirmed by blotting for the conversion of myosin light chain 3B (LC3BI) to 
LC3BII. This conversion occurs at the onset of autophagy 33, and indicates mTOR is 
being inhibited. Treatment with either concentration of rapamycin increased LC3BII 
levels approximately 3-fold, indicating inhibition of mTOR signaling and consequent 
upregulation of autophagy (Figure 11). However, as neither starvation nor rapamycin-
induced inhibition of mTOR signaling affected SMN protein levels in this cell line, it is 





Figure 11. Ras activation inhibits rapamycin-mediated downregulation of SMN 
protein levels. Western blot analysis of SMN, tubulin and LC3BI/II in BJeLR cells 
(human fibroblasts expressing the oncogenic HRasV12 isoform) treated with 5nM or 50nM 
of the mTOR inhibitor rapamycin. Graph quantification of SMN, LC3BI and LC3BII 
levels normalized to actin is shown below. Data represents the average of two 
independent samples ± standard deviation. *Increased levels of LC3BII, a post-
translational conversion product of LC3BI used as a marker of activation of autophagy, 
demonstrates activity of the mTOR pathway in this cell line, and the ability of rapamycin 
to inhibit mTOR signaling in these cells. However, activation of Ras signaling prevents 




inhibition-mediated decrease in SMN protein level. This modulation of the SMN-
downregulating effect is likely at a point downstream of mTOR, as rapamycin treatment 
demonstrates that the signaling from the mTOR complex is still functional and able to be 
inhibited in the BJeLR cells. 
 
SMN downregulation is mediated by the proteasome 
 
Although SMN has been identified to be a substrate of the proteasome 22,34, serum 
starvation-mediated inhibition of mTOR signaling is generally considered an inducer of 
autophagy 30. As other proteins have been demonstrated to be substrates of both the 
proteasome and autophagic degradative pathways 35, inhibitors of each process were 
tested to determine which could rescue the decrease in SMN upon serum starvation. SMA 
patient fibroblast cells were serum starved for 24 hours and simultaneously treated with 
either 25µM chloroquine (CHQ), an inhibitor of autophagy 36, or 2.5µM MG-132, a 
proteasome inhibitor 37. I additionally tested cuspin-1 (10µg/ml) in this assay as well, to 
determine whether cuspin-1 treatment would modulate this phenotype. Treatment with 
CHQ or cuspin-1 did not rescue the decrease in SMN protein levels upon serum 
starvation. Only the proteasome inhibitor MG-132 was able to rescue the levels of SMN, 
and it was able to do so completely (Figure 12A).  
As chloroquine is not an extremely potent inhibitor of autophagy, to confirm that 
inhibition of autophagy did not rescue SMN protein levels in serum starved cells, two 
additional autophagy inhibitors, Bafilomycin A1 38 and ammonium chloride (NH4Cl)39, 





Figure 12. Inhibitors of autophagy cannot rescue starvation-mediated 
downregulation of SMN protein levels. (A) Western blot analysis of 9677 SMA patient 
fibroblast cells serum-starved for 24 h and treated with either 25µM chloroquine (CHQ) 
(autophagy inhibitor), 10µg/ml cuspin-1 or 2.5µM MG-132 (proteasome inhibitor). 
Graph quantification of SMN protein levels normalized to tubulin. Serum starvation leads 




chloroquine or cuspin-1, however treatment with MG-132 results in complete rescue, 
indicating the decrease in SMN protein levels is mediated by the proteasome. Testing of 
the autophagy inhibitors (B) ammonium chloride (NH4Cl) or (C) Bafilomycin A1 
demonstrated the same inability of autophagy inhibitors to rescue starvation-mediated 
downregulation of SMN protein levels. Graphs quantify fold change in SMN normalized 
to loading controls. Western blot in (C) additionally shows LC3B staining; the significant 
upregulation of LC3BII indicates inhibition of autophagy. For all figures, data represents 






prevents acidification of the lysosomal vacuole. Ammonium chloride, a weak base, 
neutralizes the acidity of the lysosomal compartment. These autophagy inhibitors also 
failed to rescue the decrease in SMN protein levels upon serum starvation (Figure 12B 
and C). 
To confirm that the decrease in SMN protein levels upon serum starvation is 
mediated by the proteasome, serum-starved SMA patient fibroblast cells were treated 
with several different proteasome inhibitors: MG132, lactacystin and MG262 37. All three 
proteasome inhibitors rescued SMN levels to the same degree, although in this 
experiment the rescue was not complete, as cells were starved for 9 hours prior to 
addition of the proteasome inhibitors (Figure 13). These experiments demonstrate that 
serum starvation strongly downregulates SMN protein levels, and this decrease can be 
rescued by inhibition of the proteasome. However, the mechanism resulting in this 
downregulation is still unclear. The decrease in SMN protein levels could be the result of 
either translational inhibition with normal degradation rates, or due to stimulation of 
degradation. Further studies will be required to determine the mechanism relevant to 
starvation-induced decrease of SMN protein levels. 
 These data demonstrate that SMN protein levels are strongly downregulated upon 
inhibition of mTOR signaling via either serum deprivation or by treatment with the small 
molecule rapamycin. This decrease could be inhibited by the co-treatment of various 
proteasome inhibitors, indicating that the downregulation of SMN protein levels is 
mediated by the proteasome. Interestingly, neither serum starvation nor rapamycin 
treatment had an effect on SMN protein levels in cells expressing an oncogenic isoform 






Figure 13. Starvation-mediated downregulation of SMN protein levels is prevented 
by proteasome inhibitors. Western blot analysis of 9677 SMA patient fibroblast cells 
serum starved for 24 h and treated with either DMSO (-), 25µM chloroquine 
(CHQ)(autophagy inhibitor), or the proteasome inhibitors MG132 (2.5µM), lactacystin 
(lacta)(10µM) or MG262 (2µM). Graph shows quantification of SMN normalized to 
actin as loading control, data represents the mean ± standard deviation, n=2. The 
autophagy inhibitor chloroquine shows no effect, however treatment with any of the 




from mTOR which results in decreased levels of SMN protein in non-oncogenic cells. 
Identification of the mechanism by which mTOR signaling modulates SMN levels, as 
well as the Ras effector pathway inhibiting mTOR modulation, may reveal novel insights 




Small molecule upregulators of protein abundance are an under-utilized class of 
bioactive compounds, with the potential to elucidate protein regulation and function. The 
work presented here defines a straightforward method for identifying small molecule 
upregulators of a target protein’s abundance. These compounds have two important uses. 
First, based on the premise that upregulating the abundance of a target protein will 
increase its level of cellular activity, such compounds could act as protein function 
activators, allowing dose-dependent and reversible studies on the effects of increasing 
protein function. Discovery of small molecule activators has mainly focused on 
identifying compounds that increase the intrinsic activity of the steady-state levels of 
proteins. Small molecule activators have been identified for a handful of targets, such as 
caspases 40, the proteasome 41 and several cell surface receptors 8,42,43. However, the 
number and classes of protein targets for these direct activators are likely as limited as 
those for inhibitors of protein functions. In comparison to inhibitors, upregulators are not 
restricted to specific protein families, as they do not rely on the protein of interest being 
directly “druggable”, generally defined as the presence of a catalytic region that interacts 




advantage of targeting members of the regulatory pathways of the protein of interest, 
greatly increasing the range of protein families that can be modulated in this manner. 
The second advantage of small molecule upregulators is their utility as probes to 
investigate the pathways involved in regulating the levels of a target protein. As many 
currently intractable conditions fall into the category of loss of function diseases, such as 
Spinal Muscular Atrophy, cystic fibrosis and Duchenne muscular dystrophy 45, 
elucidation of the pathways governing the abundance of the disease gene products may 
identify new therapeutic candidates. Additionally, small molecule upregulators of 
sufficient potency and efficacy have the potential to be developed into lead therapeutics. 
Using a high-throughput screening approach for identification of small molecule 
upregulators of protein abundance, we discovered three small molecule upregulators of 
the Survival of Motor Neuron (SMN) protein. SMN has been shown to be involved in 
many cellular processes, such as pre-mRNA splicing 46 and β-actin mRNA localization to 
neuronal growth cones 47. SMN protein levels are decreased in the loss of function 
neurodegenerative disease Spinal Muscular Atrophy 48, making it a target of interest for 
both research and biomedical applications. The most active scaffold identified in our 
screen, a bromobenzophenone analog designated cuspin-1 (Chemical Upregulator of 
SMN Protein -1), was utilized as a probe to reveal a novel regulatory pathway governing 
SMN protein abundance. Treatment of Type I SMA fibroblast cells with cuspin-1 
resulted in a 50-100% increase in endogenous SMN protein levels, as well as a 
concomitant increase in the phosphorylation of Erk. Since the major pathway responsible 
for phosphorylation of Erk is the Ras-Raf-MEK cascade 19, we expressed constitutively 




~270-300% increase in SMN protein abundance. Mechanistic studies revealed that this 
upregulation was due to Ras-mediated enhancement of SMN translation rate. 
Increasing the translation rate of a target protein is an unusual mechanism of 
action, though recent studies suggest that translation regulation may have a role in diverse 
cellular process such as cancer, aging and mitochondrial function 49. As the mammalian 
target of rapamycin (mTOR) protein is a highly conserved regulator of translation 50-52, 
we investigated whether mTOR signaling could be involved in Ras-mediated regulation 
of SMN protein levels. Inhibition of mTOR signaling via starvation or small molecule 
inhibition resulted in a robust 40-60% decrease in SMN protein levels, indicating that 
mTOR is capable of modulating SMN protein levels. Of note, the downregulation of 
SMN mediated by mTOR could be completely rescued by increasing Ras signaling via 
expression of an oncogenic isoform of Ras. Cuspin-1’s inability to rescue may be due to 
its inability to activate the Ras signaling pathway as strongly as constitutively active Ras, 
or due to the shorter time frame of Ras activation with compound treatment versus a cell 
line stably expressing constitutively active Ras. These results indicate that mTOR 
signaling is involved in regulation of SMN protein levels, and that this pathway may be 
involved the robust upregulation of SMN protein levels due to increased Ras signaling. 
The findings of SMN protein regulation by the mTOR and Ras pathways may be 
relevant to each other, as the mTOR and Ras pathways have shown to be linked via 
feedback loops. Inhibition of mTOR by rapamycin has been demonstrated to result in 
increased phosphorylation of Erk via Ras 53. Additionally, mTOR inhibition has also been 
shown to increase receptor tyrosine kinase signaling upstream of Ras activation, resulting 




activation increases SMN protein levels while mTOR inhibition decreases SMN protein 
levels, this specific feedback loop may not be relevant to SMN protein regulation. 
Future studies defining the mechanism by which increased Ras signaling affects 
translation of SMN protein could identify pathways of interest for SMA and perhaps 
other loss of function diseases. Although Ras is best known for its oncogenic properties, 
its ability to upregulate non-oncogenic proteins, such as SMN, demonstrate potential 
therapeutically beneficial downstream consequences of Ras activation. There is also 
significant evidence for a pro-survival effect of Ras activation, especially in neurons, 
where Ras has been shown to be activated by pro-survival neurotrophic factors 55. 
Expression of constitutively active isoforms of Ras (CA-Ras) has shown beneficial 
effects on the survival and outgrowth of cultured chick embryonic neurons 56. 
Additionally, in a mouse model of motor neuron degeneration, neuron-selective 
expression of CA-Ras resulted in complete rescue from lesion-induced degeneration 57). 
The identification of the mechanisms downstream of Ras activation resulting in cell 
survival could lead to novel therapeutic targets for diseases resulting from pathological 




Type I spinal muscular atrophy (SMA)-affected human primary fibroblasts were 
obtained live with low passage number (Coriell Cell Repositories/#GM03813, 




(MEM) with Earle's salts and non-essential amino acids (Invitrogen/#10370-021) 
supplemented with 15% (v/v) fetal bovine serum (FBS) (Invitrogen/#26140-079), 2 mM 
L-glutamine (Invitrogen/#25030-081), and antibiotics (100,000 units penicillin/L MEM, 
100 mg streptomycin/L MEM) (Invitrogen/#15140-122).  Cells were allowed to grow in 
50 mL of the aforementioned medium at 37°C with 5% carbon dioxide in 175 cm2 tissue 
culture treated flasks (Corning/#431080). The foreskin fibroblast-derived BJ cell lines 
were cultured in DMEM (Invitrogen/#11995-040) supplemented with 10% (v/v) FBS, 
2mM L-glutamine and antibiotics. Cells were grown under the same conditions as SMA 
cell lines. 
Small Molecule Libraries Selected for Screening 
The commercially available small molecule libraries selected for screening 
consisted of the National Institute of Neurological Disorders and Stroke (NINDS) 
Custom Collection of Known Bioactives (1,040 compounds), the Annotated Compound 
Library (ACL) (2,337 compounds), the TIC library (a select composite from TimTech, 
InterBioScreen and Chembridge totaling 23,685 compounds) (15), and the Comgenex 
library (20,000 compounds).   
A second unique set of small molecules, designated the Blood-Brain Barrier 
(BBB) libraries, were selected from five commercially available compound libraries. 
These libraries contain a total of 1,322,183 unique structures which were subjected to in 
silico filtering using MOE 2004.03. All compounds were pre-processed by assigning 
polar hydrogen atoms and charges according to the MMFFx forcefield. Salts were 




for reactive functional groups and unsuitable scaffolds, as defined by Hann et al. (38) 
using a SMILES-string-based search method. We then proceeded to assess the BBB-
penetrating potential of the compounds that passed the first two filtering steps by 
constructing a set of filters to predict logBB (logarithm of brain to blood partitioning 
ratio).  The molecules' logBB values were predicted using a model trained on 73 
compounds with experimentally determined logBB values and validated on a set of 36 
CNS positive and negative drugs. The obtained model gave an R2 = 0.8225 for the 
training and R2 = 0.6989 for the validating set. Of note, the predictions gave no false 
negatives in this data set.  
From this screen, 126,877 compounds with predicted logBB values greater than 
zero (on a log scale from -3 to +6) were selected. A value of zero indicates equal 
partitioning between the blood and brain, while a positive value indicates that the 
compound would partition preferentially into CNS tissues compared to plasma. Of these 
compounds, we discarded those with molecular weights less than 250 or containing three 
or more aromatic rings. These filters were designed to eliminate very simple compounds 
or planar compounds that might intercalate into DNA. 
The final 79,691 compounds passing these filters were submitted to clustering to 
assess their diversity and to remove close structural analogs, which are frequently created 
during syntheses used by commercial vendors. This clustering was achieved by 
annotating the compounds with MACCS (Molecular Design Limited) structural keys; the 
clustering itself was performed using the Jarvis-Patrick method. Molecular similarity was 




procedure yielded 27,577 structurally distinct clusters from four vendors. Three vendors 
(Asinex, Chembridge and Life Chemicals) were chosen based on pricing, and one 
compound from each cluster was purchased, yielding a library of 22,795 compounds 
likely to cross the blood-brain barrier and to be drug-like.  
Preparation of Compound Libraries for Primary Screening 
Compound libraries were either obtained at a concentration of 4 mg/mL in 
dimethyl sulfoxide (DMSO) or were solubilized in DMSO and plated at this 
concentration in 384-well, clear, polypropylene, 13mm deep "mother" plates 
(Greiner/#781280).  These stocks were diluted into media to create "daughter" plates as 
follows: 148 μL of Dulbecco's Modified Eagle's Medium (Invitrogen/#11995-040) were 
dispensed using a Biomek FX into each well of a 384-well, clear, polypropylene, 22mm 
deep daughter plate (Greiner/#781270).  Two μL from the mother plate were transferred 
to the daughter plates and thoroughly mixed using a Beckman Biomek FX workstation. 
This resulted in a compound concentration of 53.33 μg/mL in each well of the daughter 
plates. 
Primary Screen 
GM03813 cells (herein referred to as “#3813”), GM09677 cells (“#9677”), and 
GM00232 cells (“#232”) were trypsinized, centrifuged at 214g (1000rpm with 19.2cm 
rotor radius) for five minutes and resuspended in culture media at a concentration of 
420,000 cells/mL.  Thirty-six μL of cell suspension were dispensed into each well of a 




Elmer/#6007680) using a Biomek FX, for a concentration of 15,000 cells/well.  Four μL 
from the daughter plate was transferred to each assay plate using a Biomek FX, resulting 
in a final compound concentration of 5.33 μg/mL per well.  The plate was covered with 
the supplied lid and incubated at 37°C and 5% carbon dioxide for 48 hours. All 
compounds were tested in triplicate. 
Cytoblot Fixation, Permeablization and Antibody Staining 
After 48 hours incubation with small molecules, the growth medium was 
aspirated out of each assay plate, and 30 μL of ice cold (-20°C) methanol was added to 
each well for fixation and permeabilization using a Biomek FX.  The plates were 
incubated for 5 minutes on ice, after which the methanol was aspirated and the primary 
antibody solution was immediately added. Twenty μL of 10% (v/v) goat serum 
(Invitrogen/#16210-072) in PBS with 0.1% Tween® 20 (Aldrich/#274348) containing 
primary antibody (see below for dilutions) was dispensed to each well using a Biomek 
FX. Plates were sealed using a Velocity11 PlateLoc and incubated overnight at 4°C. The 
following day, the seals were removed and the primary antibody solution was aspirated 
out of each assay plate. Twenty uL of secondary antibody in the same blocking buffer 
was dispensed into each well using a Biomek FX. Plates were incubated for one hour at 
room temperature prior to signal detection. HRP SMN cytoblot: mouse anti-SMN (BD 
Transduction Laboratories/#610647) (1:3,000 dilution) and goat anti-mouse-HRP (Santa 
Cruz Biotechnology/#sc-2031) (1:9,000 dilution) 




After the one hour incubation period, the secondary antibody solution was 
aspirated out of each assay plate. Fifty μL of 10% (v/v) goat serum in PBS with 0.1% 
Tween® 20 were added to each well using a Biomek FX, to rinse out unbound secondary 
antibody.  After 10 minute incubation on ice, the solution was aspirated.  Twenty μL of 
enhanced chemiluminescence (ECL) reagent were added to each well using a Biomek 
FX.  ECL reagent is composed of two solutions mixed together immediately prior to use 
– Solution A: 5 mL Tris (pH 8.5) (Roche/#0604205) and 4 μL H2O2 (Sigma/#H1009); 
Solution B: 5 mL Tris (pH 8.5) (Roche/#0604205), 22 μL 90 mM coumaric acid 
(Sigma/#C9008), and 50 μL 250 mM luminol (Fluka/#09253).  Luminescence was read 
using a Perkin Elmer Victor 3 microtiter platereader (#1420-041) equipped with an 
infrared filter, using a 0.8 s integration time per well.  Data was exported and evaluated in 
Excel.  
Dose-response experiments 
Compounds showing activity in the primary screen were retested in dilution 
series, daughter plates of the hit-containing mother plates were recreated (as described 
above).  For the “step-daughter” plates, fifty-eight μL of DMEM (as diluent) were 
dispensed using a Biomek FX into every well (except for columns 8 and 15) of an empty, 
384-well, clear, polypropylene, 22mm deep plate (Greiner/#781270).  One hundred and 
sixteen (116) μL of hit compound in media (53.33μg/ml) were transferred using the 
Span-8 head of a Biomek FX from the daughter plate to the step-daughter plate.  Picked 
hits were dispensed in columns 8 and 15 using rows C through N (one well per 




was performed by the Biomek FX Span-8 head: compounds in column 8 were diluted 
through column 13, and compounds in column 15 were diluted through column 20. All 
compounds were tested in triplicate. 
Robotic Scripts and Settings 
BioMek FX (software version 2.5e) method files are available upon request. 
Analog Synthesis 
Solvents and starting materials were purchased from Sigma-Aldrich and used 
without further purification. Analogs were synthesized using chlorination and Friedel-
Crafts acylation. Briefly, 50-100mg of 5-bromonicotinic acid, or desired nicotinic acid, 
was dissolved in ~10mL of anhydrous dimethyl chloride. Thionyl chloride (1.2 mEq) was 
added to solution. Reaction progress was monitored using pH paper. Once complete, 
solvent was removed under high vacuum. Acyl chlorides were coupled to desired 
benzene derivative in anhydrous dimethyl chloride with aluminum trichloride (1.3 mEq), 
overnight. Unreacted starting materials were removed by aqueous extraction and products 
were purified by chromatography in hexanes/ethyl acetate. Identity and purity was 
confirmed by mass spectrometry. Yields ranged between 20-75%, providing sufficient 
material for testing. Synthetically prepared cuspin-1 and cuspin-2 showed similar activity 
to that of the commercially sourced compounds, verifying the identity of the compounds. 




SMA patient fibroblast lines were plated at 30,000 cells per well in a 6-well plate 
~24 hours prior to compound treatment. Cells were treated with desired concentration of 
compound for 48 hours. Cells were harvested at <75% confluence, confluence may be 
lower due to compound toxicity. Cells were washed twice in ice-cold PBS and lysed by 
scraping in 100 μL ice-cold lysis buffer (50mM HEPES, 40mM NaCl, 2mM EDTA, 
0.5% Triton-X, 1.5mM Na3VO4, 50mM NaF, 10mM Na-pyrophosphate, 10mM Naβ-
glycerophosphate, Roche protease inhibitor tablet). Insoluble materials were spun out by 
centrifugation at 10,621g for 10 minutes at 4°C. Supernatants were boiled with SDS-
PAGE sample buffer prior to being separated on a 4-12% Bis-Tris NuPage gel in 1X 
NuPage MES running buffer. Proteins were transferred to a PVDF membrane using 
Invitrogen iBlot blotting system, setting P3 for 6 minutes and 40 seconds. Membranes 
were blocked in Odyssey blocking buffer (LI-COR/#927-40010) for 20 minutes at room 
temperature, then incubated overnight at 4°C with primary antibodies (see below for 
dilutions). Membranes were washed three times in TBS with 0.1% Tween-20, then 
incubated for 45-60 minutes with 680nm-conjugated anti-mouse IgG secondary antibody 
at 1:3,000 (Invitrogen/#A21058) and 800nm-conjugated anti-rabbit IgG secondary 
antibody at 1:3,000 (LI-COR/#926-322110). Signals were detected and quantified using 
the LiCor Odyssey system and software (LI-COR Biosciences). 
Antibodies: mouse anti-SMN (BD Biosciences/#610647) (1:1,000), rabbit anti-actin 
(Santa Cruz Biotechnologies/#sc-1616-R) (1:3,000), mouse anti-alpha tubulin (Santa 
Cruz Biotechnologies/#sc-32293) (1:5,000), rabbit anti-phospho-Erk1/2 (Cell 
Signaling/#9101S) (1:1,000), rabbit anti-Erk1/2 (Cell Signaling/#9102)(1:3,000), rabbit 




Signaling/#9272)(1:2,000), mouse anti-NRas (EMD Biosciences/#OP25) (1:2,000), 
mouse anti-eIF4E (BD Biosciences/#610269)(1:2,000), mouse anti-Smac/DIABLO (BD 
Biosciences/#612244)(1:1,000), mouse anti-GAPDH (Santa Cruz Biotechnologies/#sc-
47724)(1:5,000) and rabbit anti-LC3B (Cell Signalling/#2775S)(1:1,000). 
Retroviral preparation and transduction 
To prepare the retroviral supernatants, 2×106 Plat-GP cells (Cell biolabs/#RV-
103) were seeded per 10cm culture dish in DMEM supplemented with 10% (v/v) fetal 
bovine serum (FBS), 2 mM L-glutamine, and antibiotics (100,000 units penicillin/L 
MEM, 100 mg streptomycin/L MEM) and 5µg/ml G418 (Invitrogen/#11811-031). Cells 
were allowed to attach overnight. The following morning pVSV-G helper plasmids with 
the MigR1 vector either empty or containing NRasG12D were co-transfected into the Plat-
GP cells using FuGENE 6 Transfection Reagent (Roche/#11-814-443-001). Thirty hours 
post-transfection, culture media was replaced by Viral Collection Media (VCM, normal 
culture media with 30% (v/v) FBS). VCM was collected and replaced twice at 12 hour 
intervals to collect viral particles released into the supernatant. Viral supernatant was 
filtered through 0.45 micron filters prior to use or storage at -80°C. For transduction, 
#3813 SMA patient fibroblast cells were plated at 2×105 cells per well into a 6-well plate 
and allowed to attach overnight. The following day, the infection cocktail was prepared 
by mixing 0.75mL viral supernatant, 1.25mL growth media, and 2µL of 8mg/mL 
polybrene (Sigma/#H9268). The culture media in each well was replaced with the 




radius) for 90 minutes before incubation. Cells were cultured for two days prior to 
harvesting. 
RT-qPCR of SMN transcripts 
RNA was harvested from 5x106 cells using the Qiagen RNeasy Kit as per 
manufacturer’s protocol. RNA from each sample (2µg) was reverse transcribed using 
Applied Biosystems Taqman® kit (N808-0234) as per manufacturer’s protocol. 
Quantitative PCR was performed on 7300 Real-Time PCR System (Applied Biosystems) 
using 1X Power SYBR Green PCR Master Mix (Applied Biosystems/#4367659), 77ng 
cDNA and 0.15µM primers per well in a MicroAmp Optical 96-well plate (Applied 
Biosystems/#N801-0560). The cycle times of the smn transcripts were normalized to 
cycle times for hypoxanthine guanine phosphoribosyltransferase (hprt) as loading 
control. Amplification conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C 
for 15 sec and 60°C for 1 min. ΔΔCT was calculated after normalization to hprt 
expression. Primer sequences: smnFL-forward: 5’-CAAAAAGAAGGAAGGTGCTCA-









Cells were seeded at 5x106 cells per 10cm dish and allowed to attach overnight. 
For methionine/cysteine starvation, cells were rinsed twice in PBS and incubated for 30 
minutes in starvation media: Met/Cys-free DMEM (Invitrogen/#21013-024), 10% 
dialyzed FBS (v/v) and 2mM L-glutamine. After the starvation period, cells were pulsed 
with 100µCi TRAN35S-Label Metabolic Labeling Reagent (MP/#015100907) for one 
hour. Cells were lysed in 1 mL IP Buffer (50mM Tris [pH 7.75], 250mM NaCl, 200mM 
EDTA, 150mM MgCl2, 0.3% NP-40, 1% Empigen BB and Roche protease inhibitor 
tablet), scraped and insoluble materials were spun out at 10,621g for 10min at 4°C. 
Lysates were pre-cleared with 20µL Protein A/G-agarose bead slurry (Pierce/#20421) for 
30 minutes, supernatants were transferred to tubes containing 30µL Protein A/G-agarose 
pre-coupled to 2.5µg mouse anti-SMN antibody (BD Biosciences/#610647) and 
immunoprecipitated overnight at 4°C. After SMN IP, lysates were transferred to tubes 
containing 30µL Protein A/G-agarose pre-coupled to 2µg rabbit anti-actin antibody 
(Santa Cruz Biotechnologies/#sc-1616-R) and immunoprecipitated for 4 hours at 4°C. 
Beads were washed three times in IP buffer, and bound proteins were eluted by boiling in 
SDS-PAGE buffer. Samples were run on NuPAGE 4-12% Bis-Tris gels (Invitrogen/ 
#WG1402BOX) in 1X NuPAGE MES running buffer, fixed in 50% methanol + 10% 
acetic acid, and dried before exposing overnight to phosphorimager screen. Bands were 
imaged using a Storm phosphorimager (Molecular Dynamics) and quantification was 
performed using ImageQuant software (Molecular Dynamics). Values are reported as 
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Chapter 3. High-throughput screening hit validation for Huntington’s Disease 
 
Phenotypic small molecule screening in neurodegenerative diseases 
 
Phenotypic small molecule screening is often the appropriate option when searching for 
small molecule modulators of diseases with complex physiopathology. This applies especially to 
neurodegenerative diseases, as they are often pleitropic and inherently difficult to study, due to 
the complex and interconnected nature of the nervous system. Cell culture models of these 
disease states, while rarely recapitulating all aspects of a diseased organism, are a simpler and 
more cost-effective way to study cell death in poorly-understood neurodegenerative disorders 1. 
The combination of phenotypic small molecule screening and cell culture models of 
neurodegenerative diseases has the potential to reveal novel insights into the mechanisms of cell 
death relevant to these disease states.  
 
Pathogenesis of Huntington’s disease 
A strong example of the value of small molecule screening in a cell culture model of a 
neurodegenerative disease is reported in work by Hoffstrom and colleagues. The focus of this 
screen was to identify small molecule inhibitors of cell death caused by the gene responsible for 
Huntington’s disease (HD), the mutant huntingtin (htt) gene. Huntington’s disease is an 




in exon 1 of the htt gene 2. Wild-type htt contains between 6 and 35 CAG triplicates, which code 
for glutamines, however expansion above 36 repeats results in disease 3. The age of onset and 
speed of disease progression correlate strongly with the length of the polyglutamine expansion. 
Expression of a mutant allele of htt in an organism results in degeneration of neurons, mainly in 
the basal ganglia and cortex 4 5. As the basal ganglia is responsible for sending inhibitory signals 
to the motor cortex, this pattern of neuronal loss causes chorea, involuntary dance-like 
movements, characteristic of Huntington’s patients 4.   
 
Huntingtin protein 
Htt is an essential gene highly expressed in neuronal tissues 6-7. Normal Htt protein is 
approximately 350kDa, with no significant homology to other proteins. It has been suggested to 
be involved in clathrin-mediated endocytosis 8, intracellular vesicle trafficking 9 and has been 
shown to be highly concentrated on microtubules 10, however its exact cellular functions remian 
unclear.  
Mutant huntingtin protein, similar to other proteins containing expanded polyglutamine 
tracts, is toxic to specific neuronal subpopulations, most predominantly the medium spiny 
neurons of the striatum. The mutant form of Htt has been implicated in the alteration of many 
functions of key importance in neurons, including cytoskeletal integrity 11, gene expression 12, 
response to excitotoxicity 13, translation 14 and signaling 15.  
Although mutant Htt affects many vital cellular pathways, the mechanism resulting in 




human patients, however, have provided strong evidence implicating activation of the apoptotic 
pathway 16-20. However, there is no clear link between mutant Htt and apoptotic cell death. In 
order to gain more information about the connection between mutant Htt expression and cell 
death, Hoffstrom, et al. screened 47,000 compounds in the search for inhibitors of 
polyglutamine-induced cell death in a cell culture model of Huntington’s disease 21. The 
neuronal-like cell line utilized for screening, rat pheochromocytoma (PC12) cells, stably express 
an ecdysone-inducible pathogenic htt mutant with 103 glutamines in its polyglutamine tract 
(Q103). These cells faithfully replicate mutant Htt-induced cell death 22. From this screen, five 
structurally distinct inhibitors of polyglutamine-induced apoptosis were identified (Figures 14 
and 15). These compounds not only rescue cell viability, they also restore normal cell 
morphology.  
The small molecule inhibitors of mutant Htt-induced cell death were utilized as probes in 
target identification studies, in efforts to identify the missing link between polyglutamine 
expression and cell death. The target of these inhibitors was identified as protein disulfide 
isomerase (PDI), an oxidoreductase chaperone protein which catalyzes disulfide bond formation 
and rearrangement 23-24.  
 
Protein misfolding and chaperones in neurodegenerative disease  
PDI is a well-described chaperone protein generally residing in the endoplasmic 
reticulum (ER) 25. The ER is responsible for the proper folding of its many substrate proteins in 





Figure 14. Cell based (PC12) model of mutant huntingtin protein misfolding and cell 
toxicity. (a) Cells transfected with an inducible plasmid containing wild-type huntington exon 1 
(HTT-Q25) show diffuse protein expression throughout the cytosol (24 h post-induction with the 
ecdysone analog tebufenozide, Teb). EcRE, ecdysone responsive element; VBE, VP16-ecdysone 
receptor chimera; CMV-bA, cytomegalovirus enhancer-β-actin promoter, neor-PKG, neomycin 
resistance. (b) Cells transfected with the same plasmid containing mutant, polyQ huntington 
exon 1 (HTT-Q103) show perinuclear inclusion bodies at 24 h post-induction (red arrows). (c) 
Cell viability of mutant huntingtin-expressing cells (measured by Alamar Blue fluorescence at 48 
h post-induction). Cell death induced by HTT-Q103 can be rescued by treatment with a general 
caspase inhibitor, Boc-D-FMK (FMK; 50µM). (d) Primary screening results of 2,036 




compounds that rescue Q103-induced cell death are shown in red; confirmed hit (thiomuscimol) 






Figure 15. Dose-response curves for hit compounds that suppress Q103-induced apoptosis. 
The viability of tebufenozide-induced HTT-Q25 (blue) and HTT-Q103 (red) cells was detected 
by Alamar Blue fluorescence and plotted as a percentage of uninduced cells at 48 h post-
induction. (a) 16F16, (b) arteannuin B, (c) BBC7M13 (D13), (d) BBC7E8, (e) thiomuscimol, (f) 
muscimol (inactive analog of thiomuscimol; single atom substitution shown in red in compound 




the ER also contains mechanisms by which to monitor the fidelity of folding. These quality 
control mechanisms only release correctly folded protein through the secretory pathway while 
targeting misfolded proteins for degradation, via a process termed ER-associated protein 
degradation (ERAD) 26. When the ER quality control systems have determined that a protein is 
terminally misfolded, the target protein is retrotranslocated into the cytosol for proteolytic 
degradation by the ubiquitin-proteasome system 27. The ER can responds dynamically to cellular 
alterations which affect the thermodynamic stability of protein folding, in a process called the 
unfolded protein response (UPR) 28. UPR is triggered upon the accumulation of unfolded protein 
in the ER lumen, which initiates a coordinated set of signaling pathways designed to attenuate 
protein synthesis and modify transcription 29. This process provides a feedback loop to increase 
the ER’s ability to cope with maintaining proper protein folding under changing cellular 
conditions 30. Poor ER quality control mechanisms, resulting in activation of UPR, have been 
associated with neurodegenerative disease 31 and this pathway has been associated with neuronal 
death 32. 
 
Protein disulfide isomerase in Huntington’s disease 
PDI is a member of the thioredoxin superfamily 33, and consists of six domains: a, b, b’, 
x, a’ and c 34-35. Each of these domains, with the exception of x, contain the active site CXXC 
motif characteristic of thioredoxin family members, however only two (a and a’) have been 
shown to be catalytically active 36. The b and b’ domains are considered to be important for 
substrate recognition 37. Although many groups have attempted to solve the structure of full-




successfully crystallized 38. The structures of the individual domains of mammalian PDI have 
been solved, however, although mainly through the use of solution NMR. These include the a 
domain (PDB: 1mek) 39-40, b domain (PDB: 2bjx) 36,41, b’x domains (PDB: 3bj5) 42 as well as bb’ 
domains (PDB: 2kl8) 43 and a’ domain (PDB: 1x5c) 25. Together, these structures provide an 
overall framework describing the structure of full-length PDI. 
PDI contains a classic KDEL ER-retention sequence and is highly enriched within the 
endoplasmic reticulum 44, however it has been observed to present in other cellular 
compartments 24,45-46 and has even been shown to be actively exported from the ER in certain cell 
types 47. The functions of PDI outside of the ER are poorly understood, however it was found to 
re-localize to ER-mitochondrial junction points upon induction of mutant Htt expression and 
induce mitochondrial outer membrane permeabilization (MOMP) 21. MOMP initiates an intrinsic 
apoptotic pathway via release of cytochrome c and Smac/DIABLO from the mitochondria, 
which in turn activate caspase-mediated cell death 48. Activation of MOMP is governed by the 
Bcl-2 family proteins; oligomerization of the pro-apoptotic proteins Bax and Bak promote the 
release of apoptotic factors, while the anti-apoptotic Bcl-2 can inhibit the activation of these 
proteins and subsequent activation of apoptosis 49-52. 
While the mechanism resulting in induction of apoptosis is unexpected, in retrospect, it is 
not altogether surprising that an ER chaperone protein would be involved in mediating mutant 
Htt-induced apoptosis. Expanded polyglutamine proteins are generally considered misfolded and 
have a tendency to aggregate, causing ER stress by activating the ER quality control 
mechanisms. ER stress, in turn, can activate MOMP 53. Stimulation of the unfolded protein 




the endoplasmic reticulum associated protein degradation (ERAD) pathway 56. Furthermore, ER 
stress has been implicated in HD pathogenesis 57, and has been shown to upregulate the levels of 
PDI protein 58. It is possible that extended activation of UPR, results in the pathway switching 
from a protective function to an active cell death mechanism, and that the UPR-responsive 
protein PDI mediates this pro-apoptotic function. 
My efforts in this project were aimed at elucidating the mechanism linking poly-Q htt to 
apoptosis via PDI. This included validating apoptosis as the death pathway relevant to PDI-
induced cell death in the PC12 HD model used in our assays, and demonstrating that increased 
PDI expression could directly result in cell death, in order to complement the in vitro studies 
which demonstrated PDI-induced MOMP in isolated mitochondria. Lastly, we began 
crystallization studies in order to identify the binding mode of the PDI inhibitors identified in the 
high-throughput screen for small molecule inhibitors of mutant Htt-induced cell death. Although 
the crystallization trials have yet to offer any solid results, these studies have assisted in 
validating the role of PDI in a pro-apoptotic, mitochondrial-mediated pathway relevant to 
polyglutamine-induced cell death.  
 
Validation of PDI as a mitochondrial-mediated pro-apoptotic stimuli 
 
Rescue of mutant Htt-induced cell death by Bcl-2 
Although the cellular pathway by which expanded polyglutamine Htt induces cell death 





Figure 16. Overexpression of the anti-apoptotic protein Bcl-2 rescues from mutant Q103-
HTT induced cell death. (A) Cell viability of Q103-HTT expressing cells, measured by Alamar 
Blue fluorescence at 48 h post-induction with tebufenozide (Teb). Overexpression of Bcl-2, by 
viral transduction of a Bcl-2 expression plasmid, rescues cell death. Expression of a control 
protein, Lac-Z, has no effect. Bcl-2 expression rescues to a similar extent as the small molecule 
PDI inhibitor D13 (BBC7M13;10µg/mL), and does not show additive rescue upon co-treatment 




have supported apoptosis as a mechanism involved in the pathogenesis of HD 16-20. To determine 
whether mutant Htt protein expression induces apoptosis in the PC12 cell line used in our assays, 
we overexpressed the anti-apoptotic protein Bcl-2 and examined its effect on mutant Htt-induced 
cell death. Overexpression of Bcl-2 in the Q103 PC12 background resulted in an 88% rescue of 
viability from tebufenazide-induced expression of mutant Htt protein (Figure 16A). In 
comparison, the negative control Lac-Z demonstrated no rescue in comparison to the 
untransfected control, but could be rescued by the small molecule PDI inhibitor D13. Viral 
transduction increased Bcl-2 expression levels approximately 4-fold (Figure 16B). Bcl-2 
overexpression rescued both cell viability, as well as cell morphology (Figure 17). Inhibition of 
mutant Htt-induced cell death by the classical anti-apoptotic protein indicates that induced Q103 
PC12 cell death is mediated by apoptosis. Further studies using RNAi to deplete the levels of the 
pro-apoptotic proteins Bak and Bax confirmed the importance of apoptosis for mediating cell 
death in this cell line 21. 
Next, we wanted to determine whether the small molecule PDI inhibitors identified in the 
screen prevented Q103 Htt-mediated apoptosis by acting via the same pathway as Bcl-2. If the 
two factors acted independently, co-treatment should result in a higher level of rescue than Bcl-2 
overexpression alone. If the two factors affect the same pathway however, no additional rescue 
should be observed upon co-treatment. The level of rescue observed with Bcl-2 overexpression 
was not increased by addition of the small molecule PDI inhibitor D13 (Figure 16A), suggesting 
that these two factors rescue mutant Htt-induced cell death via the same cellular pathway leading 





Figure 17. Overexpression of the anti-apoptotic protein Bcl-2 rescues morphology as well 
as viability from mutant Q103-HTT induced cell death. PC12 cells transfected with an 
inducible plasmid containing the pathogenic Q103-HTT mutant fused to GFP display shrunken 
morphology and cell death 48 h post-induction of protein expression with tebufenozide (Teb). 
Overexpression of the anti-apoptotic protein Bcl-2 rescues both cell numbers and normal cell 
morphology, indicating complete rescue from cell death. The level of rescue is similar to that 






Overexpression of PDI isoforms A1 and A3 
 
Previous studies determined that the small molecule inhibitors of expanded 
polyglutamine Huntingtin (Q103-Htt) protein-induced cell death were acting via inhibition of 
protein disulfide isomerase (PDI) 21. As expression of Q103-Htt in the PC12 cell line was 
hypothesized to result in cell death by activation of a pro-apoptotic activity of PDI, we examined 
the possibility that the increased levels of PDI achieved by ectopic overexpression would be 
sufficient to induce cell death. PC12 cells containing an ecdysone-regulated pathogenic Q103-
Htt fragment were transfected with Blasticidin-selectable plasmids expressing either PDI A1, 
PDI A3 or Lac-Z as negative control. Transfected cells were seeded into 384-well assay plates 
and selected with Blasticidin at 36 hours post- transfection. At 48 hours post-transfection, 
Alamar Blue, a viability dye, was added to wells. Alamar Blue is metabolized by live cells, and 
viability can be quantified by measurement of fluorescence of the metabolized dye. Cells were 
incubated with Alamar Blue for 18-24 hours before fluorescence quantification. Transfection 
with either PDI A1 or PDI A3 resulted in approximately 70% decrease in viability, compared to 
transfection with the LacZ negative control (Figure 18). As these cells are uninduced, this 
indicates that PDI toxicity is a downstream effect of mutant Htt expression. PDI-induced cell 
death could be dose-dependently rescued by treatment with the PDI inhibitors 141 and 16F16, 
thereby confirming that increased levels of PDI are sufficient to cause cell death in a cultured 
neuronal cell model and that these small molecules can rescue cells from PDI-induced cell death 
(Figure 18). Interestingly, this effect was not isoform-specific, suggesting a level of redundancy 






Figure 18. Overexpression of PDI leads to loss of cell viability in Q103-PC12 cells. 
Transfection of Q103-PC12 cells (uninduced) with plasmids expressing either the PDI A1 or A3 
isoform leads to 70% loss of cell viability (measured by Alamar Blue fluorescence 48 h post-
transfection), compared to cells expressing the control protein Lac-Z. Loss of cell viability can 







Mitochondrial outer membrane permeabilization (MOMP)  
 
Previous work had demonstrated that during Q103 Htt-induced death, PDI re-localizes to 
accumulate on or near the mitochondria 21. Further investigations lead to the discovery that 
purified PDI could induce mitochondrial outer membrane permeabilization (MOMP), a hallmark 
of apoptosis51,59, in isolated mitochondria. To determine whether PDI-induced MOMP proceeded 
through the Bax/Bak-mediated apoptotic pathway 60, I isolated mitochondria from Q103 PC12 
cells and the same cell line stably expressing Bcl-2, an anti-apoptotic protein able to antagonize 
Bax/Bak, to investigate Bcl-2’s activity in a MOMP assay. While Q103 PC12 cells demonstrated 
strong activation of MOMP upon incubation with PDI, Bcl-2 overexpressing cells were resistant 
to PDI-induced MOMP (Figure 19). This result indicates that the mechanism by which PDI 
induces MOMP is an active pathway involving the BH3 domain-containing Bcl-2 family 
proteins, and further strengthens the connection between PDI and apoptotic cell death in this cell 
culture model of Huntington’s disease. 
 
Crystallization condition screening for the a domain of PDI isoforms A1 and A3  
 
Screening efforts have identified several small molecule inhibitors of PDI’s activation of 




mechanism by which these compounds bind to and inhibit PDI remained unclear. The ideal 
method to elucidate the binding mode of these small molecules would be co-crystallization with  
 
Figure 19. Overexpression of Bcl-2 rescues from PDI-induced MOMP in isolated 
mitochondria. PC12 cells transfected with inducible plasmids expressing either the pathogenic 
Q103-HTT or wild-type Q25-HTT huntingtin protein undergo mitochondrial outer membrane 
permeabilization (MOMP) upon 1.5 h incubation with 6U purified PDI. MOMP was assessed by 
release of the inner membrane protein Smac/DIABLO from the isolated mitochondria. Control 
samples, treated with 1mg/ml BSA, demonstrate no release of Smac, however PDI-treated 
samples show 50-60% release of Smac. Mitochondria isolated from Q103-PC12 cells 






their target. However, as expression and purification tests of full-length PDI were not yielding 
protein of sufficient quality, we chose to test a catalytic domain of PDI, the a domain. As the 
catalytically active domains of PDI were identified as the likely mediators of PDI’s pro-apoptotic 
activity 21, we endeavored to identify favorable conditions for crystallization of the a domain of 
the PDI isoforms A1 and A3. Bacterial expression plasmids expressing His-tagged a domains of 
PDI A1 and A3 were created, expressed in BL-21 E. coli and the resulting protein was isolated 
via affinity purification followed by size-exclusion chromatography (see Methods) (Figure 20). 
These plasmids demonstrated moderate expression, and post-purification yields were on average 
6mg/L culture. Some yield was lost to oligomers during size-exclusion chromatography, 
however the high concentrations required for crystallization were attainable, as the His-tagged a 
domains of PDI A1 and A3 were highly soluble, remaining in solution at concentrations of 
120mg/mL. This protein may be able to be further concentrated, however higher concentrations 
were not tested. The purified proteins (at 40-100mg/ml) were seeded into sitting-drop 
crystallization trays containing commercially available crystallization solutions, utilizing a 
Mosquito nanoliter liquid handling system. However, after regular observation over a period of 
eight months, no crystals were detected in any of the conditions, likely due to the extremely high 
solubility of this protein domain. 
Proteins with more stable structures are more likely to crystallize, therefore we attempted 
to stabilize the protein utilizing small molecules inhibitors of PDI. Several small molecules were 




and cystamine, which has been shown to ameliorate the phenotype of several animal models of 
HD 63-65 and has demonstrated PDI inhibition in our PDI activity assays 21. Unfortunately, the  
 
Figure 20. Expression and purification of the PDI A1 a domain for crystallization trials. 
Samples from several stages of protein purification were separated on a SDS-PAGE gel which 
was Coomassie-stained. Protein was harvested from E. coli BL21 cells expressing the 6XHis-




purification on agarose-Ni2+ resin, size-exclusion chromatography and final concentration of 
purified protein for crystallization trials. Multiple oligomers of the PDI a domain are visible post 
affinity purification, however they are removed upon size-exclusion chromatography. 
purified PDI a domains precipitated out of solution upon addition of dimethyl sulfoxide (DMSO) 
to final concentrations as low as 0.1%. As PAO demonstrated limited solubility in aqueous 
solutions, and could reach only moderate concentrations in DMSO (25mg/ml), it could not be 
used for crystallization trials. DNTB and cystamine were both highly soluble in aqueous 
conditions, and cystamine was selected for crystallization trials as it had shown strong activity in 
various PDI inhibition assays 21.  
The crystallization trays containing the commercially available solution sets Cryo I, Cryo 
II and Wizard II were selected for cystamine co-treatment crystallization trials, as these trays had 
shown the highest level of PDI a domain precipitation in past trials. PDI A1 a domain at 
100mg/mL was co-seeded with 1mM cystamine into sitting drop crystallization trays. However, 
after regular observation over a period of six months, no crystal formation was detected. In fact, 
addition of cystamine appeared to solubilize the protein further, as some conditions which had 
resulted in protein precipitation in previous trials were now clear of precipitate, and no 
conditions showed enhanced precipitation. Although we have been unable to identify conditions 
favorable for crystallization of the a domains of the PDI A1 and A3 isoforms, the optimization of 
protein isolation conditions and the production of highly stable, soluble PDI constructs can be 






 Defects in protein folding have been linked to many neurodegenerative diseases 66-68, in 
particular diseases associated with expression of mutant polyglutamine proteins 69-70. However, 
the connection between protein misfolding and neuronal cell death remains enigmatic. In order to 
investigate this mechanism, small molecule screen was performed in a cell culture model of 
Huntington’s disease (HD). HD is caused by an expansion in the trinucleotide CAG repeat in 
exon 1 of the huntingtin (HTT) gene. The polyglutamine expansion (polyQ) causes the protein to 
misfold and aggregate, leading to neuronal cell death via an unknown mechanism 71. Human and 
animal studies have implicated apoptosis as the death-inducing pathway 16,72-73, however little 
connection had been made between misfolded polyQ proteins and initiation of the apoptotic 
cascade.  
Investigations into the targets of the small molecule inhibitors of mutant polyQ Htt-
induced cell death identified protein disulfide isomerase (PDI) as their target. PDI has been 
extensively demonstrated to be one of the chaperone proteins involved in the endoplasmic 
reticulum (ER) protein folding quality control mechanisms 26,74. Induction of chaperone proteins, 
such as PDI, has been suggested to be beneficial in models of polyglutamine diseases 16,75-77. 
However our investigations propose that extended induction of pathways responding to protein 
misfolding results in initiation of a pro-apoptotic effect of PDI.  
Expression of pathogenic polyQ-Htt was shown to result in concentration of PDI at the 
ER-mitochondrial junction points, where it may initiate apoptosis via a yet-undefined 
mechanism. In vitro evidence of a pro-apoptotic effect of PDI was demonstrated in isolated 




incubation with purified PDI. MOMP is part of an intrinsic apoptosis-initiating cellular pathway; 
permeabilization of the mitochondrial membrane results in release of cytochrome c, Smac and 
other factors which activate caspases and initiate the apoptotic cascade 48. PDI-induced MOMP 
was prevented in mitochondria isolated from cells overexpressing the anti-apoptotic protein Bcl-
2 78, indicating this effect was both specific and mediated via the classical mitochondrial outer 
membrane Bcl family proteins. Overexpression of Bcl-2 also rescued from cell death due to 
pathogenic polyQ-Htt expression, demonstrating the relevance of this pathway to HD.  
As preliminary studies of the novel PDI inhibitors in a model of Alzheimer’s disease 
appeared positive 21, further study of this novel pro-apoptotic mechanism linking protein 





Cell lines and reagents 
PC12 cells stably expressing a geneticin-selectable plasmid expressing Q103 Htt exon 1 fused to 
GFP under control of an ecdysone-regulated promoter, allowing induction of the toxic protein by 
addition of the ecdysone analog tebufenazide. Cells were propagated in PC12 cell media 
(DMEM (Invitrogen/#12430-047), 10% Cosmic Calf Serum (Fisher/#SH3008703), 2 mM L-




streptomycin/L MEM) (Invitrogen/#15140-122) and 500µg/mL geneticin) at 37°C and 9.5% 
CO2.  
 
Q103 PC12 plate-based viability assay 
Trypsinized Q103 PC12 cells were resuspended at 250,000 cells/mL in PC12 cell media. 
40µL/well of cell suspension was pipetted into 384-well assay plates (Corning/#3712). Cells 
were incubated with desired treatment for two days, after which the viability dye Alamar Blue 
(Invitrogen/#DAL1100) was added to assay plates to a final concentration of 10%. Cells were 
incubated with Alamar Blue for an additional 16-24 hours. Alamar Blue fluorescence was read 
on a PerkinElmer Victor3 platreader at 590nm (530nm excitation, 0.1 second integration). Cell 
viability was normalized to control cells.  
 
PDI overexpression 
PC12-Q103 cells (2×106 cells) were transfected with pLenti6 plasmid (Invitrogen/#V496-10) 
expressing either PDI A1, PDI A3 or LacZ using the Amaxa nucleofection system (Amaxa 
nucleofection reagent V, program U-29). Immediately following transfection, cells were seeded 
into 384-well assay plates (10,000 cells/well) and incubated for 36 hours (37°C, 9.5% CO2) prior 
to selection with Blasticidin (5µg/mL) and addition of a 2-fold, 7-point dilution of each 
compound into triplicate assay wells. Alamar Blue was added to a final concentration of 10% 




fluorescence. Statistical significance of compound rescue was determined by ANOVA and 
Dunnett’s post hoc comparison test at 0.01 confidence. 
 
Bcl-2 overexpression 
Cells (PC12-Q103) were transfected with pLenti6-Bcl-2 or pLenti6-LacZ cDNA via Amaxa 
nucleofection (5×105 cells, Amaxa nucleofection reagent V, program U-23 or G-13) or lentiviral 
infection (two serial spinning infections, 10 µl polybrene, 1.5hrs, 2,250rpm, 37°C).  Cells were 
selected for 1-2 weeks with Blasticidin (5 µg/ml) prior to viability assays, which were performed 
as described previously. 
 
Mitochondrial isolation 
Mitochondria were isolated from 1×107 cells per experiment. Cells were harvested by 
trypsinization, centrifugation at 1,000rpm for 5 minutes, washed once in 10mL PBS and 
centrifuged again. Pellet was resuspended in 250µL extraction buffer (250mM sucrose, 0.1% 
bovine serum albumin, 10mM HEPES (pH 7.5), 5mM KCl, 1.5mM MgCl2, 1mM EGTA and 
1mM EDTA), and cells were allowed to swell on ice for 3 minutes. Cells were lysed by 
trituration through a 30G needle for approximately 15 strokes. Samples were incubated on ice for 
15 minutes and then centrifuged at 700rpm for 5 minutes to pellet unlysed cells and nuclei. 
Supernatant was transferred to a fresh eppendorf tube and centrifuged at 10,000rpm for 15 




resuspended in 100µL of extraction buffer. Mitochondrial concentration was determined by 
absorbance at 280nm. 
 
MOMP assay 
Isolated mitochondria were normalized to 12µg/µL, and 17µL of mitochondrial suspension 
(~200µg) were utilized per sample. For samples at a different pH than 7.5, mitochondrial 
aliquots were centrifuged at 10,000rpm for 15 minutes at 4°C, and resuspended in extraction 
buffer at desired pH. To each sample, either BSA (1mg/mL) or PDI (6U) were added, volumes 
were normalized with extraction buffer.  Samples were incubated in a 36°C water bath for 90 
minutes. After incubation with enzyme, samples were centrifuged at 10,000rpm for 15 minutes at 
4°C. Supernatants were transferred to a fresh centrifuge tube containing 10µL 5X SDS-PAGE 
sample buffer. To the pellet, 40µL of 1X SDS-PAGE sample buffer was added. Samples were 
incubated at RT for 15 minutes prior to boiling to allow thorough solubilization of the lipid-rich 
mitochondrial pellets. Samples were separated on 4-12% Bis-Tris NuPage gel in 1X NuPage 
MES running buffer. Transfer and immunoblotting were performed as described earlier. Degree 
of MOMP was calculated by Western blot for Smac released from the mitochondrial pellet (P) 
into the supernatant (S). Antibodies: mouse anti-Smac/DIABLO (BD 
Biosciences/#612244)(1:1,000). 
 




BL-21 DE3 E. coli cells (Stratagene/#230132) were transformed with pET-15b plasmids (EMD 
Biosciences/#69661-3) containing the catalytic a domain of either PDI A1 or PDI A3. 
Transformed cells were grown in liquid culture at 37°C to an O.D. of approximately 0.4, after 
which the temperature was decreased to 25°C. Once the culture reached O.D. of 0.6, protein 
production was induced by adding Isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 1mM. After overnight induction, the cells were harvested by centrifugation at 
4,000 rpm for 25 minutes at 4°C. The pellet was resuspended in 35mL RS buffer (50mM Tris-
HCl, pH 8.0, 150mM NaCl and 2mM β-mercaptoethanol) per liter of culture, and magnesium 
chloride was added to a final concentration of 5mM. The cell suspension was sonicated on ice 
(tip limit 8, 50% duty cycle, 10-15 cycles of 20 seconds on and 20 seconds pause). Insoluble 
materials in the cell lysate were cleared by centrifugation at 13,000 rpm for 30 minutes at 4°C. 
Cleared lysates were added to 2mL of Ni2+-agarose bead slurry (Sigma/#P6611) washed with 
10mL RS buffer and rotated for 1 hour at 4°C to permit binding of the His-tagged protein to the 
Ni2+ beads. After batch binding, beads were separated from lysate using a gravity column. Beads 
were washed with 40mL of RS buffer, and 20mL Low Imidazole Buffer (RS buffer + 10mM 
imidazole) to remove loosely bound proteins. His-tagged protein was eluted with Elution Buffer 
(RS buffer + 250mM imidazole); final volumes ranged from 3mL to 7mL of eluted protein 
solution. 
 Eluted protein solution was concentrated to approximately 4mL using centrifugal 
filtration devices with a molecular weight cut-off of 10kDa (Millipore/#42406) prior to loading 
onto a S300 column equilibrated with Column Buffer (20mM tris-HCl, pH 8.0 and 150mM 




was concentrated to the desired level utilizing larger volume centrifugal filter units with a 10kDa 
MW-cutoff (Fisher/#2997).  
 
Crystallization condition screening 
Commercially available crystallization solutions were utilized: Index (Hampton Research/#HR2-
144), SaltRx (Hampton Research/#HR2-108), Natrix (Hampton Research/#HR2-116), PEG/Ion 
Screen (Hampton Research/#HR2-126), PEG/Ion Screen 2 (Hampton Research/#HR2-098), 
Crystal Screen (Hampton Research/#HR2-110), Crystal Screen 2 (Hampton Research/#HR2-
112), Crystal Screen Cryo (Hampton Research/#HR2-122), Crystal Screen Lite (Hampton 
Research/#HR2-128), Wizard I (Emerald BioSystems/#EBS-WIZ-1), Wizard II (Emerald 
BioSystems/#EBS-WIZ-2), Cryo I (Emerald BioSystems/#EBS-CRYO-1), Cryo II (Emerald 
BioSystems/#EBS-CRYO-2)  JCSG Core Suite I (Qiagen/#130924) and JCSG Core Suite II 
(Qiagen#130925). These sets total 918 crystallization conditions, although they may not all be 
unique. Crystallization solutions were formatted into 96-well plates, and 80µL per well was 
utilized for screening in 96-well Crystal Ex plates (Corning/#3785). Using an automated 
nanoliter pipetting system (mosquito, TTP Labtech), for each well 0.5µL of purified protein was 
combined with 0.5µL well solution and deposited into the drop well of sitting drop 
crystallization. For samples including cystamine, cystamine dihydochloride (Sigma/#C121509) 
was added to the protein solution for a final concentration of 1mM. Plates were sealed, incubated 
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Chapter 4. Conclusions and Future Directions 
 
 This thesis presents the use of small molecule probes in the investigation of the 
neurodegenerative diseases Spinal Muscular Atrophy and Huntington’s Disease. Work 
performed on Spinal Muscular Atrophy identified a small molecule upregulator of the 
disease gene product, Survival of Motor Neuron (SMN). Investigation into its mechanism 
of action revealed regulation of SMN protein levels by the small GTPase Ras and the 
nutrient-sensing translational regulator mammalian target of rapamycin (mTOR) kinase. 
Work performed on Huntington’s Disease (HD) were aimed at validation of the 
mechanism of action of a HD-mediated cell death inhibitor.  
 
I. Spinal Muscular Atrophy 
 
Ia. Summary 
 The neurodegenerative disease Spinal Muscular Atrophy is caused by decreased 
levels of the Survival of Motor Neuron protein, however the cellular pathways regulating 
its levels are largely undefined. Therefore we developed, optimized and implemented a 
screen to identify novel small molecule upregulators of the Survival of Motor Neuron 
protein. The optimal hit from this screen, Chemical Upregulator of SMN-1 (cuspin-1), 
was utilized as a chemical probe in efforts to identify the cellular pathways being 
modulated resulting in increased SMN protein levels. Mechanistic studies revealed 
modulation of Ras signaling, and confirmatory studies lead to the discovery that 




SMN protein levels via increased translation. The involvement of altered translation led 
us to investigate the role of the mammalian target of rapamycin (mTOR) in this Ras-




 Neurodegenerative diseases tend to be inherently difficult to study, due to a 
general inability to acquire the disease cells for experimentation as well as the complex  
nature of neuronal systems. Reductionist methods, such as utilizing cell culture models of 
disease states, can offer great insight into the cellular mechanisms underlying disease. We 
have used fibroblasts from human SMA patients to identify novel small molecules and 
pathways regulating the levels of the disease gene product, SMN protein. While 
preliminary studies suggest that these modulators may act positively in the disease tissue, 
motor neurons, more work is needed to conclusively determine their effect. Additionally, 
as increased Ras signaling has been shown to rescue neuronal cell death due to various 
neurodegenerative insults, identifying the downstream effector pathways of Ras 
responsible for SMN protein upregulation may identify cellular factors that could be 
modulated to benefit not only the SMA phenotype, but other neurodegenerative diseases 
as well. 
 
Ic. Future Directions 
 The future directions for this project are two-pronged: first, determine the 




which Ras activation upregulates SMN protein levels. To determine the relevance of 
these pathways, we would like to test the effect of cuspin-1 and expression of Ras 
isoforms on the tissue of interest in Spinal Muscular Atrophy, namely human motor 
neurons. Due to the development of robust methods for the differentiation of motor 
neurons from embryonic stem cells, we are hopeful that we may be able to test our 
hypothesis in SMA motor neurons as well. As expression of Ras has been shown to be 
beneficial in various models of neuronal outgrowth and damage 1-2, it is possible that 
activation of Ras could rescue SMA-induced neuronal outgrowth defects. However, it 
will require significant effort to identify whether these effects are due to re-establishment 
of sufficient levels of SMN protein, or due to an alternate mechanism. 
 If these mechanisms prove to be beneficial to motor neuron outgrowth in culture, 
we may endeavor to test the effect of Ras pathway activation in mouse models of SMA. 
As cuspin-1 has not shown activity in mouse cells, it is unlikely that it will prove 
functional in an animal model. Therefore, activation of Ras via expression of an 
oncogenic isoform will likely prove to be the preferable method for testing our 
hypothesis. As organism-wide expression of oncogenic Ras would likely cause 
significant undesired side effects 3, a mouse line expressing activated Ras in a neuron-
specific manner, such as described Heumann and colleagues2 would be preferred. 
Observing the phenotype of mice generated by crossing a line expressing an activated 
isoform of Ras in a neuron-specific manner with an SMA mouse model should provide 
valuable information on the efficacy of Ras activation in rescuing the motor neuron 




 Secondly, we would like to investigate the mechanism by which cuspin-1 
activates Ras as well as how increased Ras signaling results in SMN protein upregulation. 
Therefore, identification of the target of cuspin-1 would be of great interest. One method 
by which to identify cuspin-1’s target is via affinity purification, utilizing click chemistry. 
Click chemistry, also known as copper-mediated Huisgen 1,3,-dipolar cycloaddition 4, 
allows a small molecule with a terminal alkyne moiety to be selectively attacked in a bio-
orthogonal manner by an azide-coupled affinity tag. For target identification, the small 
molecule of interest must be first modified to include a terminal alkyne. While modifying 
the structure of cuspin-1 without loss of activity has been problematic, some degree of 
freedom in changing the molecular makeup has been identified at the methyl group. 
Alteration of this functional group to an ethynyl group may provide the needed ‘handle’ 
without loss of efficacy. The alkyne-modified compound can then incubated with cell 
lysate to allow binding to the target, and the cyclo-addition reaction is performed to bind 
the target protein-small molecule complex covalently to the affinity tag. The tag can then 
be affinity purified, and the proteins remaining with the tag, presumably including the 
target, can be identified by mass spectrometry. This technique has been utilized 
successfully by members of our group 5 as well as others 6-7. 
 As we have identified cuspin-1 as an activator of Ras signaling, potential targets 
include Ras guanine nucleotide exchange factors (Ras-GEF) and Ras GTPase activating 
proteins (Ras-GAP), which activate 8 and inactivate Ras signaling 9-10, respectively. 
However, activation of proteins involved in upstream signaling from various growth 




 If a potential target is found via click chemistry, follow-up studies will be 
required to confirm the compound’s mechanism of action. These include knockdown and 
overexpression studies in order to determine that the potential target has the relevant 
cellular activity, and confirmation of direct binding of cuspin-1 to the purified target 
protein via in vitro binding assays.  
We would also like to address the issue of specificity for SMN protein 
upregulation upon Ras activation. To gain a global view of the mRNAs whose 
translational activities are affected by either cuspin-1 or oncogenic Ras expression, we 
will perform a polysomal microarray, in conjunction with the Sonenberg Laboratory at 
McGill University. This technique involves sucrose gradient fractionation of cell lysates 
in order to separate mRNAs bound by one or two ribosomes, indicating they are being 
translated at a low rate, from mRNAs bound by several ribosomes (termed a polysome), 
which are producing multiple copies of the protein product. The mRNAs in each fraction 
can then extracted and identified by microarray. The shift of an mRNA from the low-
ribosomal fraction to a high-ribosomal fraction upon treatment with cuspin-1 or Ras 
expression would indicate an increase in its translation rate, and we can thereby identify, 
in a global manner, the mRNAs targeted by cuspin-1 or oncogenic Ras.  
Although preliminary work attempting to identify the relevant downstream Ras 
effector utilizing small molecule inhibitors and overexpression studies has been negative 
to date, alternate methods may yet prove successful. Creation of Ras point mutants, 
which have been demonstrated to inhibit specific Ras-effector binding events, while 
preserving others 11, may prove informative. The Ras interacting partners that can be 




activation of the Raf/MEK/Erk pathway, however preliminary studies indicate that this is 
not the relevant pathway leading to SMN protein upregulation. The RasE37G mutant is 
unable to interact with and activate Raf or PI3K, but maintains Ral-GEF binding. The 
RasT35S mutation inhibits activation of PI3K or Ral-GEF, but can activate Raf. Lastly, the 
RasY40C mutant activates PI3K, but not Raf or Ral-GEF. While these reagents may not be 
perfect, they will help determine the role, if any, that these pathways play in Ras-
mediated upregulation of SMN protein levels. 
Several lines of investigation have pointed towards an important role for 
translational regulation in SMN protein upregulation, including the identification that the 
upregulation is caused by an increase in translation rate and the involvement of the 
translational regulator mTOR. Therefore, another potential mediator of SMN 
upregulation is the eukaryotic initiation factor 4E (eIF4E), a major regulator of cap 
dependent translation 12. The activity level of eIF4E is regulated in large part by its 
availability 13, therefore we will overexpress eIF4E and determine its effect on SMN 
protein levels. To determine whether eIF4E is the downstream effector of Ras activation 
which results in upregulation of SMN protein levels, we will overexpress the translational 
repressor eIF4E-binding protein 1 (4E-BP1), which binds to eIF4E and thereby reduces 
its effective cellular concentration 14. If overexpression of 4E-BP1 prevents the increase 
in SMN protein levels upon Ras activation, this will suggest that eIF4E is a relevant 







II. Huntington’s Disease 
 
IIa. Summary 
 Huntington’s Disease (HD) is caused by an expanded polyglutamine (polyQ) 
repeat in the N-terminus of the huntingtin (HTT) gene, resulting in striatal cell death by 
an unknown mechanism. A screen for small molecule inhibitors of polyQ Htt-induced 
cell death discovered several compounds which could rescue mutant huntingtin-induced 
cell death in a cell culture model of HD.  Affinity purification studies identified the target 
of the compounds as the oxidoreductase protein disulfide isomerase (PDI), however 
mechanisms connecting PDI to cell death were lacking. Identification of re-localization 
of PDI to the membrane junctions between the endoplasmic reticulum and the 
mitochondria suggested a mitochondrial function for this normally ER-resident protein. 
The application of purified PDI to isolated mitochondria was determined to result in 
mitochondrial outer membrane permeabilization (MOMP), an initiating step in 
mitochondrially-mediated apoptosis. We utilized the anti-apoptotic protein Bcl-2 to 
validate the role of apoptosis in polyQ Htt-induced death in our HD cell culture model, as 
well as in PDI-induced MOMP in isolated mitochondria. Studies aimed at determining 
the binding mode of the small molecule cell death inhibitors to PDI were initiated, 
however as we have been unable to crystallize PDI to date, we have turned to solution 









 Many neurodegenerative diseases have been linked to expression of misfolded 
mutant proteins with expanded polyglutamine regions, however the mechanism by which 
these mutant proteins result in cell death remains unclear. We have identified and 
validated a cell death pathway linking the chaperone protein PDI to apoptotic cell death 
in HD model. Additionally, modification of this pathway has shown promise in other 
protein misfolding diseases, suggesting that this mechanism associating protein 
misfolding and apoptotic cell death may have relevance to a broader range of 
neurodegenerative diseases. 
 
IIc. Future Directions 
 First and foremost, we would like to identify the binding mode of the small 
molecule inhibitors to PDI. Efforts aimed at crystallization of the catalytic a domain of 
PDI have proven unsuccessful to date, likely due to the high solubility of the purified 
protein. To take advantage of this solubility, solution NMR structure studies have been 
initiated. Since a solution NMR structure of the PDI a domain has been published 15, this 
should facilitate studies to determine the residues interacting with the small molecules. 
Comparison of solution NMRs of the protein with and without compound should 
demonstrate spectral shifts in the residues responsible for binding to the inhibitors, and 
allow computer-aided modeling of the binding mode of these small molecules. 
 Next we would like to determine whether the enzymatic activity of PDI is 




mutants and test their efficacy in both the cell culture model of HD and in the MOMP 
assay. Additionally, we should identify whether additional effector proteins are involved 
in PDI-induced MOMP. One method for identification of PDI-interacting proteins is to 
fractionate mitochondria to isolate the mitochondrial membranes, and flow this purified 
fraction over a column containing resin-immobilized PDI. Proteins binding to PDI can 
then be identified by mass spectrometry. As an alternative or confirmatory method, we 
can use shRNAs targeting mitochondrial outer membrane proteins to screen for proteins 
involved in PDI-induced MOMP. Mitochondria can be isolated from these cell lines, and 
can be tested for their ability to undergo MOMP upon incubation with purified PDI. 
Knockdowns which result in loss of PDI-induced MOMP will be candidates for follow-
up testing. 
 Next, as these PDI inhibitors have shown efficacy in models of both HD and 
Alzheimer’s disease 5, medicinal chemistry efforts should be undertaken in order to 
perform animal studies. Our laboratory has established protocols for testing the efficacy 
of small molecules in a C. elegans model of HD in collaboration with the laboratory of 
Dr. Anne Hart 16. To perform studies in the R6/2 mouse model of HD 17 we must first 
determine and optimize the solubility, pharmacokinetic parameters, metabolic stability 
and blood-brain barrier penetration capability of these compounds. The activity of 
compounds produced in this medicinal chemistry effort should be confirmed in our cell 
culture and in vitro assays for PDI inhibition. These studies will enable optimization of 
these small molecule inhibitors of PDI in order to determine their efficacy in a 




animal models of other neurodegenerative diseases resulting from protein misfolding, 
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